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1. Abkürzungsverzeichnis 
 
DNA   desoxyribonucleic acid (Desoxyribonukleinsäure) 
eGFR  estimated (geschätzte) glomeruläre Filtrationsrate 
OCRL  okulo-cerebro-renales Lowe-Syndrom 
OMIM  Online Mendelian Inheritance in Man – Datenbank  
PCR   polymerase chain reaction (Polymerase-Kettenreaktion) 
POLtube  Polish Registry of Inherited Tubulopathies   
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2. Zusammenfassung 
2.1 Einleitung 
Die klassische Form des okulo-cerebro-renalen Lowe-Syndroms (OCRL) (OMIM 
#309000), welches 1952 erstmals beschrieben wurde (Lowe et al., 1952), ist eine  
X-chromosomale Multisystemerkrankung mit einer geschätzten Prävalenz von 1: 500.000 
(Lowe et al., 1952; Loi et al., 2006; Bökenkamp et al., 2014). Sie setzt sich aus einer Trias 
aus kongenitalem Katarakt, mentaler und verhaltenssozialer Retardierung und 
Dysfunktion des renalen Tubulus, die langsam bis zum Nierenversagen führt, zusammen. 
Meist treten okuläre Manifestationen und eine muskuläre Hypotonie mit Geburt auf, 
wohingegen die renale Beteiligung meist in den ersten Monaten im Rahmen einer 
Leichtgewichtkettenproteinurie postnatal bemerkbar wird. Weitere Merkmale des Lowe-
Syndroms können eine Wachstumsretardierung, eine Areflexie und eine 
Gelenkschwellung mit hämorrhagischer Beteiligung im Sinne einer 
Thrombozytenfunktionsstörung sein. Magnetresonanztomographisch zeigen sich 
periventrikuläre zystische Läsionen (Recker et al., 2013). Die Therapie des Lowe-
Syndroms beschränkt sich heutzutage hauptsächlich auf eine symptomatische Therapie, 
wobei die betroffenen Patienten nur in den wenigsten Fällen älter als 40 Jahre werden.  
Die molekulare Ursache des Lowe-Syndroms liegt in einer Mutation des OCRL-Gens, 
welches für das Enzym Inositolpolyphosphat-5-phosphatase (IPP-5P) codiert (Attree et 
al., 1992). Dieses Enzym konvertiert Phosphatidylinositol-4,5-biphosphonat (PIP2) zu 
Phophatidylinositol-4-phosphat (Raucher et al., 2000; Zhang et al., 1995). Es ist an der 
Adhäsion von Zytoskelettplasmamembranen und an verschiedensten Kompartementen 
im endozytischen Netzwerk beteiligt und spielt somit eine Rolle bei der Zytokinese und 
Ziliogenese. Eine Dysregulation der verschiedenen OCRL-abhängigen Prozesse erklärt 
das variable klinische Erscheinungsbild, das für das Lowe-Syndrom kennzeichnend ist. 
Im Formenkreis der renalen Tubulopathien gibt es ebenfalls die sogenannte Dent-
Erkrankung, die mit renaler Tubulopathie, Nephrolithiasis und progredienter Nieren-
insuffizienz assoziiert wird. Hierfür zeigen sich Mutationen im CLCN5-Gen ver-antwortlich. 
Interessanterweise wurden OCRL-Mutationen in Patienten mit einer Dent-Erkrankung 
entdeckt, die nun als Dent-2 bezeichnet werden (Szczepanska et al., 2014). Die 
Entdeckung von Patienten mit klinisch mildem Lowe-Syndrom und ohne okuläre 
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Beteiligung lässt darauf schließen, dass Dent-2-Erkrankungen eine milde Form des Lowe-
Syndroms darstellen (Hoopes et al., 2005; Utsch et al., 2006). Die beobachteten 
Phänotypunterschiede bei Patienten mit Lowe-Syndrom und Dent-2-Erkrankung legen die 
Vermutung nahe, dass es individuelle Unterschiede in der Kompensationsmöglichkeit des 
Enzymverlusts gibt.  
 
Die dargestellten Studien (Publikation A und B) hatten die Identifizierung neuer OCRL-
Mutationen in einem Patientenkollektiv von insgesamt 29 Patienten, die an einem Lowe-
Syndrom erkrankt waren, zum Ziel. Im beobachteten Kollektiv konnten ebenfalls zum 
ersten Mal die exakten Bruchpunkte einer kompletten Deletion des OCRL-Genes bei 
einem auffälligen Patienten bestimmt werden. Zudem konnten in dem genannten 
Patientenkollektiv erstmalig phänotypische Merkmale beschrieben werden, die bisher 
nicht mit dem Lowe-Syndrom assoziiert waren. Weiterhin wurde untersucht, ob OCRL-
Mutationen ein phänotypisches Kontinuum aufzeigen, welches selektiv bzw. zeitabhängig 
auftreten kann und ob eine Genotyp–Phänotyp-Korrelation besteht. 
 
2.2 Material und Methoden 
In Studie A wurde eine Patientenkohorte von 28, nicht verwandten Familien untersucht, 
welche alle einen Indexpatienten aufwiesen, der mit hoher Wahrscheinlichkeit aufgrund 
des klinischen Erscheinungsbildes an einem Lowe-Syndrom erkrankt war. Alle 
Indexpatienten zeigten neben den typischen okulären Symptomen (Katarakt/Glaukom), 
eine muskuläre Hypotonie und kognitive sowie verhaltenssoziale Auffälligkeiten, die mit 
einer proximalen Tubulopathie gepaart waren. Die Mehrheit des Kollektives, das einen 
Altersmedian von 7,75 Jahren aufwies, wurde aus Polen (n=19) rekrutiert. Die übrigen 
Patienten stammten aus Großbritannien (n=1), Malta (n=1), Mazedonien (n=1), Schweiz 
(n=1), Türkei (n=1) und Indien (n=1). Die Daten hierfür wurden im Rahmen internationaler 
Register und Fachgesellschaften erhoben.  
Die phänotypischen Merkmale wurden anhand klinischer Mess-, Labor- und 
Standardwerte bestimmt. Eine Leichtgewichtkettenproteinurie wurde anhand eines 
Verlustes von a1-Mikroglobulin, b2-Mikroglobulin oder retinolbindendem Protein 
diagnostiziert. Eine renale tubuläre Azidose wurde mit Hilfe der Werte des 
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Plasmabicarbonates bestimmt und Aminoazidurie anhand eines 
Ionenaustauschchromatopgraphen ermittelt. Eine Calciumausscheidung von über 
4mg/kg/24h (0,1 mmol/kg/24 h) wurde als Hypercalcämie klassifiziert. Ein chronisches 
Nierenversagen im Kollektiv wurde als eGFR < 90 ml/min per 1,73 m2 definiert. 
Gerinnungsphysiologische Auffälligkeiten der Thrombozyten wurden anhand des PFA-
100 Systems ermittelt (Siemens Healthcare, Erlangen, Deutschland).  
Die genomische DNA wurde mit einem QIAmp Extraktionsset (Qiagen, Hilden, 
Deutschland) extrahiert. Alle 24 OCRL Exons wurden im Kollektiv per Polymerase-
Kettenreaktion (PCR) amplifiziert. Die Analyse wurde mittels Sanger-Sequenzierung 
durchgeführt (3130XL Genetic Analyzer; Applied Biosystems, Foster City, Kalifornien, 
USA). Die Nukleotidbenennung erfolgte anhand der GenBank-No. NM_000276.3.  
Zur genauen Deletionsanalyse bei Indexpatient 28 wurde ein SurePrint G3 ISCA 
CGH+SNP 180k Array mit der Agilent Feature Extraction Software Version 11.5 genutzt 
(Agilent CytoGenomics 2.5; Agilent, Santa Clara, Kalifornien, USA). Anhand eines sog. 
Primerwalkings konnte final ein PCR-Produkt zur Bestimmung des Bruchpunktes 
amplifiziert und sequenziert werden.  
In Publikation B wurde die genomische DNA eines Patienten aus Sri Lanka ebenfalls mit 
dem QIAmp Extraktionssets (Qiagen, Hilden, Deutschland) extrahiert. Alle 24 Exons des 
OCRL-Gens wurden per Polymerase-Kettenreaktion (PCR) amplifiziert. Die Analyse 
wurde ebenfalls mittels Sanger-Sequenzierung durchgeführt (3130XL Genetic Analyzer; 
Applied Biosystems, Foster City, Kalifornien, USA). Die Nukleotidbenennung wurde, wie 
beschrieben, auch mit der GenBank-No. NM_000276.3 durchgeführt.  
 
2.3 Ergebnisse 
Die genetischen Analysen in Publikation A identifizierten in dem Kollektiv bei allen 
Patienten einen Defekt im OCRL-Gen.  
Es konnten zehn bisher nicht beschriebene Mutationen in den Exons 8–24 nachgewiesen 
werden. Das Mutationsspektrum im gescreenten Kollektiv setzt sich aus zehn missense-
Mutationen (35,7 %), acht nonsense-Mutationen (32,1 %) und fünf intronischen Splice-
Mutationen (17,9 %) zusammen. Bei drei Patienten (10,7 %) konnten kleine Insertionen 
bzw. Deletionen gefunden werden. Weiterhin zeigte sich bei einem Patienten ein 
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p.Asp523 Asn-Austausch, der ebenfalls bei Dent-2-erkrankten Patienten vorliegen kann. 
Bei diesem X-chromosomalen Erbgang wurden ebenfalls 23 Mütter der Patienten des 
Lowe-Patientenkollektivs untersucht. Hier zeigte sich, dass 16 Patientenmütter auch 
Träger des entsprechenden Gendefektes waren. Nur bei 7 Müttern ließ sich eine de-novo-
Mutation (30,4 %) darstellen.  
Ein Patient zeigte eine größere Deletion, wobei die letzten 14 Nukleotide von Exon 14 und 
die ersten 13 Nukleotide von Intron 14 deletiert waren. Darüber hinaus zeigte sich bei 
diesem Patienten eine 17-bp große Insertion. Bei einem weiteren Patienten konnte kein 
PCR-Produkt des OCRL-Gens amplifiziert werden, so daß die Vermutung einer 
vollständigen Gendeletion nahe lag. Die zunächst durchgeführte Arrayanalyse zeigte hier 
den Verlust von ca. 103kb, wobei die Deletion sowohl das OCRL-Gen mit flankierenden 
3’– und 5’-Sequenzen als auch Teile des SMARCA1-Gen beinhaltete. Mittels 
Primerwalking konnte bei diesem Patienten schließlich ein, den Bruckpunkt beinhaltendes 
PCR-Produkt amplifiziert werden. Eine Sanger-Sequenzierung definierte dann eine 
Deletion von genau 67865 Basenpaare (bp), die ausschließlich das komplette OCRL-Gen 
erfaßt.  
Die meisten der untersuchten Patienten und deren klinische Daten wurden durch die 
Polish Registry of Inherited Tubulopathies (POLtube) rekrutiert. Bei bisher 20 
beschriebenen Lowe-Patienten in Polen wurde mittels Hochrechnung auf die 
Allgemeinbevölkerung eine Prävalenz von circa 1: 2 000 000 in Polen ermittelt.  
Alle Patienten wiesen perinatal bzw. im weiteren Lebensverlauf einen kongenitalen 
Katarakt auf. Ebenfalls zeigte sich bei dem gesamten Kollektiv eine Proteinurie, wovon 
nur 11 von 28 (39,3%) eine Leichtgewichtkettenproteinurie aufwiesen. Alle Patienten 
wiesen die typisch charakteristischen Symptome eines Lowe-Syndromes wie eine 
Nephrokalzinose bzw. Nephrolithiasis, eine Aminoazidurie, eine Glykosurie und eine 
renale tubuläre Azidose auf. In 64,3 % ließ sich ebenfalls eine chronische 
Nierenerkrankung Stufe 2 oder größer nachweisen.  
Weiterhin ließen sich in dem Patientenkollektiv auch hämatologische Auffälligkeiten 
nachweisen, die zuvor von Lasne et al. erstmals beschrieben wurden (Lasne et al., 2010).  
Dabei handelt es sich um Thrombozytopenien, eine hypochrome mikrozytäre Anämie und 
Plättchenfunktionsstörungen.  
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Darüber hinaus konnte bei zwei Patienten zum ersten Mal das klinische Erscheinungsbild 
der Hyperosmie und Hyperakusis in Zusammenhang mit einem Lowe-Syndrom 
beschrieben werden. Weitere Untersuchungen konnten leider aufgrund des fehlenden 
Erscheinens der Patienten nicht durchgeführt werden.   
In Publikation B konnte bei dem Patienten aus Sri Lanka eine, bisher nicht in der Literatur 
beschriebene, hemizygote Mutation c. 1427C>T (pThr476Ile) gefunden werden, die 
ebenfalls bei der Mutter des Patienten als Trägerin dieser Mutation nachgewiesen werden 
konnte.  
2.4 Diskussion 
Die Identifizierung des Mutationsspektrums der untersuchten OCRL-Mutationen und die  
Anzahl der de-novo-Mutationen in Publikation A bestätigt die in der Literatur 
beschriebenen Befunde für die Prävalenz verschiedener OCRL-Mutationen (Hichri et al., 
2011). Es konnten circa ein Drittel de-novo-Mutationen gefunden werden, welche 
hauptsächlich die OCRL-Exons 8 – 24 betreffen. Bisher sind in der Literatur nur zehn 
große Deletionen (Hichri et al., 2011) bei Lowe-Patienten beschrieben, wobei nur zwei 
das gesamte OCRL-Gen betreffen (Hichri et al., 2011; Peverall et al., 2000; Addis et al., 
2007). Erstmal konnte in Publikation A eine Deletion mit ihren exakten Bruchpunkten bei 
einem Lowe-Patienten bestimmt und analysiert werden. Hier zeigte sich der Verdacht 
eines Replikations-slippage, welches nur einen einzelnen Strang betrifft. In diesem Fall 
zeigte sich im involvierten Bereich vierfache eine Alu-Sequenz, welche bereits bei dem 
Gen LPAR6 in der Literatur den gleichen Effekt zeigte und als Markersequenz für die 
betreffenden Deletionen dienen könnte (Mahmoudi et al., 2012). 
Im Hinblick auf die Prävalenz des Lowe-Syndroms sind in der Literatur keine genauen 
Daten beschrieben. Die amerikanische und italienische Lowe-Gesellschaft schätzen die 
Prävalenz auf 1: 500 000 (Loi, 2006). In der Studie zeigte sich im Hinblick auf Polen eine 
Prävalenz von 1: 2 000 000. Dies kann einerseits bedeuten, dass die Erkrankung seltener 
als bisher angenommen vorkommt oder aufgrund des variablen klinischen 
Erscheinungsbildes nicht richtig diagnostiziert wird (Keilhauer et al., 2007; Pasternack et 
al., 2013).  
Besonders im Hinblick auf die renalen Phänotypen zeigte sich eine selektive tubuläre 
Dysfunktion, welche im beschriebenen Kollektiv von Publikation A nachvollzogen werden 
kann (Böckenhauer et al., 2008). Die Variabilität der renalen Manifestation steigt mit dem 
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Alter, wobei kein Lowe-Patient in diesem Kollektiv die komplette Manifestation eines 
renalen Fanconi-Syndroms zeigt (Böckenhauer et al., 2008; Kleta et al., 2008). In der 
Literatur wird die renale tubuläre Azidose bei nur etwa einem Drittel der Lowe-Patienten 
beschrieben (Bökenkamp et al., 2009). Die Beobachtung, dass in der vorliegenden Arbeit 
zwei Drittel des Patientenkollektives eine renale tubuläre Azidose aufwiesen, verdeutlicht 
die Variabilität des Erscheinungsbildes, aber auch die Bedeutung von einheitlichen und 
genau definierten Kriterien zur Bestimmung einer renalen tubulären Azidose. 
 
Eine chronische Nierenerkrankung wird mit einer hohen Prävalenz bei Lowe-Patienten 
gefunden. Zu ihrer Diagnose benötigt man  die akkurate glomeruläre Filtrationsrate (GFR), 
wobei ein korrigierter k-Wert von 26 zur Kalkulation der geschätzten glomerulären 
Filtrationsrate (eGFR) in der Schwartz-Haycock-Formel genutzt wird. Die Ursache hierfür 
liegt in der niedrigen Muskelmasse bei Lowe-Patienten (Böckenhauer et al., 2008). Ein 
Ignorieren dieses Sachverhaltes kann zur Fehldiagnose und zum Nicht-Erkennen der 
Erkrankung führen. Eine Korrelation zwischen der eGFR und der Körpergröße konnte bei 
Lowe-Patienten bislang nicht nachgewiesen werden (Bökenkamp et al., 2009).  
Es zeigte sich weiterhin, dass bei der Identifizierung von Lowe-Patienten auch die 
hämatologischen Parameter entscheidend sein können. Matzaris et al. beschrieben das 
Vorkommen des OCRL-1-Proteins in humanen Thrombozyten, sodass eine Korrelation 
mit Blutungsstörungen bei Lowe-Patienten nachzuweisen war (Matzaris et al., 1994). Im 
besonderen bei der Carbamazepin-Behandlung von Krampfanfällen, welche bei Lowe-
Patienten gehäuft vorkommen können, kann sich eine Verstärkung des hämatologischen 
Störungsbildes zeigen, sodass bei der Therapie von Lowe-Patienten dies bedacht werden 
muss (Verrotti et al., 2014).  
Als erstmals beschriebenes klinisches Erscheinungsbild zeigte sich in Publikation A eine 
Hyperakusis. In der Literatur wird über eine Interaktion des Proteins SNX9 mit der 
Aktinpolymerisation berichtet, welche eine entscheidende Rolle für die Stereozilien in der 
cutikulären Platte im Ohr spielt (Cao et al., 2013). In diesem Kontext wurde die Bindung 
des OCRL1-Proteins direkt an SNX9 in Fibroblasten beschrieben (Nandez et al., 2014). 
Das OCRL1-Protein spielt somit eine wichtige Rolle bei der Aktinzusammensetzung des 
Innenohres. In dieser Publikation konnte nachgewiesen werden, dass das klinische Bild 
des Lowe-Syndroms auch akustische Auffälligkeiten beinhalten kann 
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Eine genaue Phänotyp-Genotyp-Bestimmung lässt das Lowe-Syndrom aufgrund der 
großen klinischen Variabilität nicht zu. Allerdings zeigte sich ein Kontinuum des 
Phänotyps, welches bisher in der Literatur nur bei Dent-2-Patienten spezifisch 
beschrieben wurde. In Studie A zeigte sich nun erstmals dieses Kontinuum auch bei 
Lowe-Patienten. Weiterhin kann sich in der magnetresonanztomographischen Diagnostik 
bei Lowe-Patienten eine Oligogyrierung und eine vereinfacht gyrale Musterung darstellen, 
welche  sowohl als Hinweis auf Krampfanfälle als auch kognitive und mentale 
Einschränkungen verstanden werden kann (Hanefeld et al., 1999; Pang et al., 2008).  
Eine weitere Besonderheit, die das in der Publikation A untersuchte Kollektiv aufzeigt und 
ebenfalls in der Literatur beschrieben wurde, ist eine Konzentration der Mutationen in den 
ersten sieben Exons bei Dent-2 und den Exons 8 – 24 bei Lowe-Patienten (Hichri et al., 
2011; Böckenhauer et al., 2012). Dies legt den Verdacht von sogenannten Hotspots für 
Mutationen im OCRL-Gen nahe und muss in Zukunft genauer untersucht werden. 
Hotspots sind einzelne Stellen oder Bereiche eines Gens, an dem gehäuft und meist die 
gleichen Mutationen auftreten können. Dieser Mechanismus kann aufgrund eines 
Gründereffekts erklärbar sein. Ein Zusammenhang dieses Effektes mit den dargestellten 
Untersuchungen des Lowe-Syndroms als X-chromosomale Erkrankung, konnte jedoch 
nicht nachweisen werden und gilt, aufgrund der geringen Reproduktionsrate der 
Patienten, als eher unwahrscheinlich (Ten Kate et al., 1984).  
In Publikation B wurde eine neue und in der Literatur nicht beschriebene Mutation bei 
einem Patienten aus Sri Lanka nachgewiesen. Diese erweitert das bisher beschriebene 
Mutationsspektrum, welches sowohl aus missense, nonsense, splice site Muationen, als 
auch aus Insertionen und Deletionen besteht.  
2.5 Ausblick 
Die vorliegenden Studien zeigen, dass genetische Faktoren bei der Entstehung des Lowe-
Syndroms eine essenzielle Rolle spielen und viele Mutationen bisher noch nicht bekannt 
sind.   
Durch die am Institut für Klinische Chemie und Klinische Pharmakologie durchgeführten 
genetischen Analysen konnten neue Mutationen im OCRL-Gen identifiziert werden, die 
bislang nicht in der Literatur beschrieben waren und die die Möglichkeit neuer 
Screeningmethoden für mögliche Mutations-Hotspots eröffnen.  
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Anhand der Größe des Kollektivs und der Anzahl an erkrankten Patienten einer 
Nationalität, konnte erstmals aufgrund der Kollektivgröße eine Prävalenz der Erkrankung 
ermittelt werden. Die bisher angenommene Prävalenz ergab sich lediglich aus 
Schätzungen der entsprechenden Lowe-Selbsthilfegruppen.  
Ebenfalls ließen sich im Rahmen der Studie Hotspots der Genloci in den Exons 8–24 
nachvollziehen. Es zeigte sich, dass hier ein besonderes Augenmerk beim zukünftigen 
Screening des Lowe-Syndroms liegen sollte. Ein Gründereffekt, der sich häufig bei 
repetitiven Mutationen zeigt, konnte anhand des Kollektives nicht nachgewiesen werden.  
Weiterhin konnten erstmals die phänotypischen Charakteristika von Lowe-Patienten 
genauer untersucht werden. Anhand der dargestellten Resultate muß angenommen 
werden, dass sowohl einzelne modifizierende Effekte bestimmter Genloci als auch 
Umwelteinflüsse einen Einfluss auf die Entwicklung und Ausprägung bei Lowe- und Dent-
2 Patienten haben können. Es werden weitere Studien benötigt um diese Einflüsse in 
Zukunft zu untersuchen und eventuelle Therapiemöglichkeiten zu entwickeln.  
Ebenfalls wurde ersichtlich, dass die Diagnostik und Erkennung von renalen 
Tubulopathien und deren phänotypischen Merkmalen aktuell unzureichend ist. In Zukunft 
sollten bessere Screeningmethoden entwickelt und Schulungen hinsichtlich des 
Formenkreises dieser Erkrankungen angeboten werden.  
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Abstract
Background The oculocerebrorenal syndrome of Lowe
(OCRL) is a rare X-linked multi-systemic disorder, al-
most always characterized by the triad of congenital
cataract, cognitive and behavioral impairment and a
proximal tubulopathy.
Methods Twenty-eight novel patients with suspected Lowe
syndrome were studied.
Results All patients carried OCRL gene defects with muta-
tional hot spots at CpG dinucleotides. Mutations previously
unknown in Lowe syndrome were observed in ten of the 28
patients, and carriership was identified in 30.4 % of the
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mothers investigated. Mapping the exact breakpoints of a
complete OCRL gene deletion revealed involvement of
several flanking repeat elements. We noted a similar
pattern of documented clinically relevant symptoms,
and even though the patient cohort comprised relatively
young patients, 32 % of these patients already showed
advanced chronic kidney disease. Thrombocytopenia
was seen in several patients, and hyperosmia and/or
hyperacusis were reported recurrently. A p.Asp523Asn muta-
tion in a Polish patient, associated with the typical
cerebrorenal spectrum but with late cataract (10 year), was
also evident in two milder affected Italian brothers with ocular
involvement of similar progression.
Conclusions We have identified clinical features in 28 pa-
tients with suspected Lowe syndrome that had not been rec-
ognized in Lowe syndrome prior to our study.We also provide
further evidence that OCRL mutations cause a phenotypic
continuum with selective and/or time-dependent organ in-
volvement. At least some of these mutants might exhibit a
genotype–phenotype correlation.
Keywords Oculocerebrorenal syndrome of Lowe .OCRL .
Cataract . CpG dinucleotides . Hyperosmia . Hyperacusis .
Thrombocytopenia
Introduction
The oculocerebrorenal syndrome of Lowe (OMIM #309000),
first reported by Lowe and colleagues in 1952 [1], is a rare X-
linked multi-systemic disorder with an estimated prevalence
of 1 in 500,000 in the general population [2]. Lowe syndrome
is characterized by the triad of congenital cataracts, cognitive
and behavioral impairment and a renal proximal tubulopathy
in almost all patients. The ocular manifestations and severe
hypotonia mostly present at birth, whereas renal involvement
appears within the first months of life [2–4], with low-
molecular-weight proteinuria (LMWP) having been demon-
strated already in the neonatal period [5]. Additional features
observed in Lowe syndrome include postnatal growth retar-
dation, independent of kidney function, areflexia, nontender
joint swelling and subcutaneous nodules. A debilitating ar-
thropathy aggravates the syndrome in about 50 % of adult
patients [3]. Occasionally, brain magnetic resonance imaging
(MRI) identifies white matter abnormalities, mainly
representing periventricular cystic lesions [6, 7]. A recent
retrospective clinical survey noted an increased risk for hem-
orrhage in patients with Lowe syndrome, attributable to de-
fects in platelet function [8]. Treatment of Lowe syndrome is
mainly symptomatic, and the life span of an affected individ-
ual rarely exceeds 40 years, mainly limited by progressive
kidney failure. However, deaths from other complications
may occur at all ages due to infection, dehydration and pneu-
monia [9].
The causative gene of oculocerebrorenal syndrome of
Lowe (OCRL) encodes the enzyme inositol polyphosphate
5-phosphatase, OCRL-1 [10], and more than 170 different
mutations have been observed in patients with classic Lowe
syndrome [11]. However, OCRL mutations are not only
found in classic Lowe syndrome, but also in milder
affected patients [11–14] who are classified as having
Dent-2 disease (OMIM #300555) [15]. OCRL-1 local-
izes to multiple compartments in the endocyctic network
(early endosomes, clathrin-coated pits, Golgi apparatus
and the basal body) and also plays a role in the matu-
ration of polarized epithelial cells and in cytokinesis and
ciliogenesis (for a detailed review, see [16, 17]). Hence,
a dysregulation of all these OCRL-1-dependent process-
es may explain the pleiotropic clinical presentation seen
in Lowe syndrome. Moreover, the observed phenotypic
continuum within patients with Dent-2 disease and
Lowe syndrome suggests individual differences in the
ability to compensate for loss of enzyme function [15].
However, the reason(s) why some OCRL mutations
manifest with the respective phenotypic spectrum re-
main(s) to be elucidated.
In the study reported here, we conducted a clinical and
genetic analysis of 28 newly identified and unrelated
patients with suspected Lowe syndrome. These investi-
gations revealed novel phenotypic features that had not
been associated with the disease in previous studies and
identified an as-yet unknown OCRL mutation in more
than one-third of the cases. We have mapped, for the
first time, the exact breakpoints of a complete OCRL
gene deletion involving several flanking repeat elements.
CpG dinucleotides represent mutational hot spots in the gene,
and for one mutant we were able to establish a striking
genotype–phenotype correlation.
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Material and methods
Subjects
Twenty-eight unrelated families with an index patient with
clinical suspicion of Lowe syndrome were investigated. For
all patients, the diagnosis of Lowe syndrome was based
on clinical criteria; that is, all affected boys showed
characteristic eye symptoms (cataract/glaucoma), muscu-
lar hypotonia and/or cognitive and behavioral impair-
ment and a proximal tubulopathy. Twenty-three mothers
of these children were also investigated for carriership.
The majority of the patients (median age 7.75 years,
range 0.7–20 years) were enrolled from Poland (n=19);
the remaining patients were from the UK (n =3),
Gibraltar (n =1), Malta (n =1), Macedonia (n =1),
Switzerland (n=1), Turkey (n=1) and India (n=1). The
study was approved by the respective local ethics com-
mittees, and after informed consent was given, blood
samples were obtained from each patient and, if avail-
able, his mother.
Assessment of phenotypic features
Urine analysis was performed on spot samples, and glycosuria
was determined by dipstick and/or formal laboratory methods.
Aminoaciduria was assessed by ion exchange chromatogra-
phy. LMWP was defined by excessive urinary loss of α1-
microglobulin, β2-microglobulin or retinol-binding protein.
Calcium excretion exceeding 4 mg/kg/24 h (0.1 mmol/kg/
24 h) was classified as hypercalciuria, as was an elevated
calcium–creatinine ratio in a spot urine sample using age-
appropriate reference values [18]. Renal tubular acidosis
(RTA) was assessed by plasma bicarbonate values and
the need for bicarbonate supplementation. Potassium
wasting was defined as repeated serum potassium levels
below the normal limits used by the local laboratory
and/or the need for potassium supplementation.
Phosphate wasting was defined as the need for phos-
phate supplementation or as a hypophosphatemia ac-
cording to local laboratory values in the presence of a
decreased tubular reabsorption rate of phosphate
(<80 %) or tubular maximum for phosphate reabsorption
[TmP/glomerular filtration rate (GFR)] normalized to the
age-appropriate lower limit of normal [19].
Estimated GFR (eGFR) was calculated using the original
Schwartz method [20]. A lower k-value of 26 was used
with serum creatinine (in μmol/l) as suggested previous-
ly [3]. Chronic kidney disease (CKD) was defined as an
eGFR of <90 ml/min per 1.73 m2. Nephrocalcinosis was
assessed by ultrasonography. MRI had been performed
in selected patients based on clinical indication. The
standard deviation score for height and body mass index
(BMI) were calculated from the World Health Organization
growth charts (http://www.who.int/growthref/en). Short
stature was defined as a height SDS of less than −2.
Prolonged closure times due to platelet dysfunction were
assessed with the PFA-100 system (Siemens Healthcare,
Erlangen, Germany).
Mutation detection
Genomic DNAwas extracted using standard procedures of the
QIAamp extraction kit (Qiagen, Hilden, Germany). All 23
exons and the alternatively spliced exon 18a of the human
OCRL gene [10] were amplified by PCR (oligonucleotide
sequences are obtainable upon request). For the mutational
analysis, the PCR-amplified DNA products were subjected to
direct automated sequencing (3130XL Genetic Analyzer;
Applied Biosystems, Foster City, CA). Initially, both strands
from the patients’ amplicons were sequenced, and carriership
in the mothers was investigated by sequencing the respective
PCR product. Nucleotide numbering is according to GenBank
entry NM_000276.3.
Deletion analysis
Array analysis in patient no. 28 was carried out using the
SurePrint G3 ISCA CGH+SNP 180k Array and Agilent
Feature Extraction Software version 11.5 (Agilent
CytoGenomics 2.5; Agilent, Santa Clara, CA). This array
includes markers with a median genomic distance of 4.3 kb
in defined regions of clinical significance [International
Standards for Cytogenomic Arrays (ISCA); http://
iscaconsortium.org]; other regions are covered with a
median genomic distance of markers of 30.5 kb. Primers
used for amplification and sequence analysis of the junction
fragment and to map the exact breakpoint were F-5′-GATT
GGGTCCTTGTCCTGGG-3′ and R-5′-GTAAAAAGCACA
AAACAGGGGC-3′.
Results
Mutation and carrier analysis
OCRL gene analysis in the 28 Lowe syndrome patients re-
vealed the presence of a single defect in all cases. As outlined
in Table 1, we detected ten previously unreported mutations,
all of which are located in exons 8–23 and comprise ten
missense (35.7 %), eight nonsense (32.1 %) and five intronic
mutations (17.9 %) affecting the respective consensus motif
for splice site recognition. An additional effect on correct
splicing can also be assumed for two of the missense muta-
tions (p.Ala861Pro, p.Ala861Thr) observed. In three patients
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(10.7 %), small insertions and/or deletions could be detected.
One patient showed a complex mutation in which the last 14
nucleotides of exon 14 and the first 13 nucleotides of intron 14
were deleted, together with a 17-bp insertion (Table 1). This
mutation predicts a p.Arg486Ser substitution and a frameshift.
Since the mutation also eliminates the normal 3′-splice site,
exon skipping, cryptic splice site usage or a read-through may
occur, which can only be verified on the mRNA level.
However, a RNA sample was not available. One patient
carried a complete gene deletion, as outlined below. In one
of our patients (no. 12) a p.Asp523Asn exchange was detect-
ed; this same mutation was recently observed in a patient with
Dent-2 disease [21].
Investigation of 23 mothers of the Lowe syndrome patients
revealed carriership in 16 females and the de novo occurrence
of the respective mutation in seven cases (30.4 %). The
c.2083C>T (p.Arg695*; Table 1) mutation was observed
twice in our patient cohort (nos. 18, 19) and occurred
de novo in both these patients. The c.2581G>A muta-
tion was observed in patients of Polish (no. 26) and
Indian origin (no. 27), also making an independent
appearance most likely. One mutation (c.940-11G>A)
was detected in two apparently unrelated families of Polish
origin (nos. 4, 5); here, an independent origin could not be
proven and, hence, a common founder responsible for this
recurrence could not be excluded.
Breakpoint analysis
Failure to amplify OCRL gene products by our standard
procedure suggested a complete gene deletion in patient 28.
Array analysis confirmed this assumption and revealed a
Table 1 Type and occurrence of
OCRL mutations detected
OCRL, Causative gene of
oculocerebrorenal syndrome of
Lowe
a Numbering according to the
cDNA sequence (GenBank NM_
000276.3) with the A of the first
coding methionine as no. 1
bAccording to Hichri et al. [11]
cMutation at CpG dinucleotide
d Addi t ional effect of this
mutation could not be predicted
e This mutation has also been
observed in a patient with Dent-2
disease [21] and his brother (this
study)
Patient Mutationa Location Consequencea De
novo
Reported
yetb
1, JC c.668C>Tc Exon 8 p.Arg230* Yes Yes
2, JL c.723-1G>A Intron 8 splice defect No No
3, ZC c.836T>C Exon 10 p.Leu279Pro ? No
4, SN c.940-11G>Ac Intron 10 splice defect No Yes
5, DJ c.940-11G>Ac Intron 10 splice defect No Yes
6, NY c.1000C>T Exon 11 p.Arg334* ? Yes
7, EZ c.1070G>T Exon 12 p.Gly357Val Yes No
8, KS c.1123C>T Exon 12 p.His375Tyr No No
9, JS c.1453_66/c.1466+1_+13del
insTCTAAAACAGACTC
TAA
Exon 14,
intron 14
p.Arg486Serfs ?d No No
10, AS c.1490G>A Exon 15 p.Trp497* No Yes
11, CF c.1499G>Ac Exon 15 p.Arg500Gln Yes Yes
12, MS c.1567G>Ac Exon 15 p.Asp523Asne No Yes
13, RD c.1567G>T Exon 15 p.Asp523Tyr No No
14, JK c.1621C>Tc Exon 16 p.Arg541* No Yes
15, KSo c.1879+5G>A Intron 17 splice defect No Yes
16, CE c.1925_26delTC Exon 18 p.Ser642CysfsX9 ? Yes
17, PM c.1927_28delGT Exon 18 p.Val643AsnfsX8 No Yes
18, JP c.2083C>Tc Exon 18 p.Arg695* Yes Yes
19, MZ c.2083C>Tc Exon 18 p.Arg695* Yes Yes
20, SP c.2313T>A Exon 20 p.Cys771* Yes No
21, BG c.2416G>T Exon 21 p.Glu806* ? Yes
22, BK c.2418G>T Exon 21 p.Glu806Asp Yes No
23, PM c.2464C>Tc Exon 21 p.Arg822* No Yes
24, KC c.2581G>C Exon 22 p.Ala861Pro, splice
defect
? No
25, RC c.2582-2A>G Intron 22 splice defect No Yes
26, DS c.2581G>Ac Exon 23 p.Ala861Thr, splice
defect
No Yes
27, MH c.2581G>Ac Exon 23 p.Ala861Thr, splice
defect
No Yes
28, MJ complete gene deletion – – No No
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maximum loss of a 103-kb fragment that comprised theOCRL
gene together with 3 ′- and 5 ′-flanking sequences
(arr[hg19]Xq25-q26.1-128.641.304x1,128.667.163-
128.725.786x0, 128.743.853x1), as well as part of the
SMARCA1 gene. Primer walking identified a junction frag-
ment of 1.752 bp in this patient and his carrier mother, and
sequence analysis defined a deletion of 67.865 bp, excluding
an involvement of SMARCA1. The first deleted nucleotide
resides at position 128.664.721, in the center of an Alu-Jb
repeat, whereas the 3′-breakpoint (last deleted nucleotide at bp
128.732.585) locates between two members (L2B and
L1MB2) of the family of long interspersed nuclear elements
(LINEs) (Fig. 1). Microhomology of two basepairs (ApC)
between the proximal and distal breakpoints could be
observed, with one of these ApC-dinucleotides being
maintained.
Prevalence of the disorder
Of the patients investigated in this study, 19 were of Polish
origin, and the largest part of the data was collected by the
Polish Registry of Inherited Tubulopathies (POLtube). There
has also been one previously reported case [22], bringing the
total number of reported patients with Lowe syndrome in
Poland to 20. This limited study cohort allows a very rough
estimate of the prevalence of Lowe syndrome in Poland
(general population of 38,544,513): approximately 1 in 2
million in the general population. However, this estimate is
A
chr X:128.664.718        128.732.586
B
OCRL
Alu Sx Alu SgAlu Jb
LTR16A
Alu Sx
L1MB2L2BL1ME3B L1ME3B L1ME3B
C
OCRL
ALU-Sx
ALU-Sx
ALU S
Deletion
- g
Fig. 1 Breakpoint analysis of a complete OCRL gene (causative gene of
oculocerebrorenal syndrome of Lowe) deletion in patient no. 28. a
Sequence analysis of the junction fragment showing the X-location of
the residues retained (arrows). Microhomology of two basepairs located
between the proximal and distal breakpoints can be observed, with one of
the ApC-dinucleotides (underlining) being maintained. b Distribution of
repetitive elements in the breakpoint flanking regions comprising (partial)
repeats: L1ME3B, L2B and L1MB2 belong to the family of long
interspersed nuclear elements (LINEs), and LTR16A is a member of
long-terminal-repeat elements of the endogenous retroviral ERVL
family; four short interspersed nuclear elements of the Alu family are
shown with their orientation indicated by arrows (http://www.
repeatmasker.org). c Owing to the orientation of the Alu repeats, a
‘triple-barrel’ structure involving one strand may have formed during
replication. Thus, the complete OCRL gene with its flanking sequences
(red line) would have been deleted following illegitimate recombination
secondary to a slip–replication mechanism [25]
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based on the assumption that all cases of Lowe syndrome have
been correctly diagnosed and captured in POLtube.
Phenotypic findings
Clinical features reported in our patient cohort are listed in
Tables 2 and 3. Congenital cataract was noted in all patients
except one (no.12), who subsequently developed this feature
at the age of 10 years. All patients presented with proteinuria,
although LMWP was not determined in 11/28 (39.3 %) cases.
According to the data available, hypercalciuria was observed
in 67.9 % (19/28) of patients, nephrocalcinosis and/or
nephrolithiasis in 42.9 % (12/28), aminoaciduria in 72.0 %
(18/25), glycosuria in 3.6 % (1/28) and RTA in 78.6 % (22/
28). Phosphate wasting was noted in 57.7 % (15/26), and 11/
25 (44.0 %) patients showed excess potassium loss resulting
in hypokalemia. Median eGFR was just below the normal
range at 78 ml/min/1.73 m2 (range: 9–120 ml/min/1.73 m2,
n=23) and CKD at stage 2 or higher (eGFR <90 ml/min) was
detected in 18 patients (64.3 %). Of the 28 patients, 32.1 %
(9/28) had moderate CKD (eGFR 30–59 ml/min/1.73 m2) and
10.7 % (3/28) had severe CKD (eGFR <30 ml/min/1.73 m2).
Data on height and BMI were available for 27 and 20
patients, respectively. Short stature was noted in 81.5 % (22/
27) of patients when compared with a normal population.
Median height SDS was −3.94 (range −0.32 to −6.84), where-
as median BMI SDS corrected for height age was 0.17 (range
3.92–1.9).
Age was inversely related to eGFR (r=−0.61, p<0.002),
but not with height SDS (r=−0.49, p<0.1). There was a direct
relationship between age and the number of features of renal
manifestations (r=0.49, p<0.007), thereby demonstrating
progression of tubular dysfunction with age. There was no
correlation between eGFR and nephrocalcinosis (r=−0.06;
p=0.7). The severity of nephrocalcinosis could not be corre-
lated as we obtained no data relating to its degree.
Hematological abnormalities were observed in nine
(32.1 %) cases: thrombocytopenia was noted in three Polish
patients (nos. 3, 5, 23) and a low-normal platelet count was
noted in three other Polish patients (nos. 10, 11, 12). A
hypochromic, microcytic anemia [hemoglobin (Hb) 8.8 g/dl]
with a normal iron profile (serum Fe, ferritin, transferrin
saturation) and an unremarkable thalassemia screen was re-
corded for the patient fromMalta (no. 11). One patient (no. 1)
showed microcytosis with a mean corpuscular volume of 69 fl
(age-appropriate normal value 74 fl) with a normal Hb level
(11.8 g/dl) and iron profile. A platelet-activation anomaly, as
described by Lasne et al. [8], was detected in two patients
(nos. 1, 6) from England and Gibraltar.
In two patients (nos. 4 and 17), hyperosmia and/or
hyperacusis were noted several times by the parents. To our
knowledge, this is the first report of these two conditions in
patients with Lowe syndrome The parents reported a
sensitivity to certain frequency and volume ranges of domestic
and environmental noise and a heightened sense of some types
of smells. Unfortunately, these conditions could not be veri-
fied by any formal assay, since the patients did not appear
following invitation.
One of our patients (no. 11) died aged 18 months with
respiratory failure following a severe right upper lobe pneu-
monia, probably due to aspiration.
Discussion
OCRL gene analysis
The mutational spectrum observed in our patient cohort is in
line with the data reviewed by Hichri et al. [11] who reported
similar values for the respective type of OCRL mutations.
Similar to these authors we also found a de novo mutation in
roughly one-third of cases. With the exception of the
p.Asp523Asn substitution (see below), none of the mutations
observed in this study have been detected in patients with
Dent-2 disease as yet and, as expected, all point mutations and
small deletions/insertions were detected inOCRL exons 8–23.
A total of ten large deletions [11], with two comprising the
completeOCRL gene have been described in previous studies
[23, 24]. Here, we report a patient with a complete gene
deletion that we investigated in detail for the first time by
precisely mapping its exact breakpoints (Fig. 1a). This dele-
tion involved half of an Alu-Jb repeat in the 5′-region of the
gene, and its 3′-break centred between two members of the
family of LINEs (L2B and L1MB2; Fig. 1b), suggesting
replication slippage involving one strand only. Four Alu se-
quences are orientated in opposite directions, and owing to
this arrangement, the formation of a ‘triple-barrel’ structure
involving one strand may have occurred (Fig. 1c). This would
have allowed strand slipping, deleting the OCRL gene with
some flanking sequences, a mechanism recently proposed for
a complete deletion of the LPAR6 gene [25]. Since the gene
flanking regions are enriched for repeat elements, a similar
mechanism may have been involved in the other two gross
OCRL deletions.
Prevalence of Lowe syndrome
No data reporting the incidence of Lowe syndrome have been
published to date. Based on the observations of the American
Lowe’s syndrome Association and the Italian Association of
Lowe’s Syndrome, a prevalence of 1 in 500,000 in the general
population has been estimated [2]. In our study, we obtained a
value for Poland of 1 in 2 million in the general population,
suggesting that either the disease is even rarer than previously
estimated, or the disease is still underdiagnosed, probably due
Pediatr Nephrol
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Table 2 Clinical findings detected in Lowe patients
Patient Agea
(years)
Low-
molecular
weight
proteinuria
Hypercalciuria Nephro-
calcinosis/
lithiasis
Aminoaciduria Renal
tubular
acidosis
Phosphate
wasting
Potassium
wasting
Glycosuria CKD
eGFR
Short
stature
(height
SDS)
Cataract Cognitive/
behavioral
impairment
Other features
1, JC 2.5 + + − nd Mild − − − + (57) + (−3.73) + Mild Microcytosis, platelet
dysfunction
2, JL 7.5 nd (P) + + + + − + − + (51) + (−4.45) + + Facial dysmorphism
3, ZC 17.5 + − − + + − + − + (22) + (−5.85) + +, Seizures Thrombocytopenia
4, SN 7 + + − − Mild + − − + (86) + (−3.78) + Tantrums, auto-
agression,
no speech
Cryptorchidism (l),
hyperacusis,
hyperosmia, joint
hypermobility
5, DJ 2 + − − + − − − − + (83) − (−1.32) + + Thrombocytopenia
6, NY 11 + + − + + − − − + (38) + (3.56) + Severe Platelet dysfunction,
renal stones
7, EZ 4 nd (P) − − − + + + − + (62) + (−3.89) + Severe Encephalo-myelocele
8, KS 8.5 + − − + + − + − − (92) + (−5.67) + +, Seizures Rickets
9, JS 16.5 nd (P) − + nd Severe + + − + (80) + (−6.23) + + Rickets, recurrent
fractures
10, AS 0.7 nd (P) − − − + − − + − (101) − (−0.64) + +, Seizures Low normal platelet
count, rickets,
facial dysmorphism,
dysmorphic
shape of thorax
11, CF 1 + + − + + + + − − + (−6.84) + + VUR, hydro-uretero
nephrosis, low-
normal platelet
count, hypochromic
microcytic anemia
12, MS 12 nd (P) + + Mild − − − − + (77) − (−0.38) +, at 10 years
of age
+ See Table 4
13, RD 4 + + + + + + + − + (88) + (−5.13) + + Recurrent fractures
14, JK 20 nd (P) + + + + + − − + (43) + (−4.8) + +, Seizures Facial dysmorphism,
rickets
15,KSo 1 + − − + + + − − − (101) + (−4.52) + + Cryptorchidism, joint
hypermobiliy,
ventriculomegaly,
periventricular cysts
16, CE 17.7 + + − Moderate + + − − + (55) + (−3.52) + Developmental delay −
17, PM 3 + + + − Mild − − − + (74) + (−2.18) + Developmental delay,
tantrums,
aggressiveness
Cryptorchidism,
hyperacusis,
rickets, joint
hypermobility
18, JP 17.5 + − − + + nd + − + (27) + (−3.86) + + Rickets
19, MZ 4 + − − + − − − − − (91) − (−0.32) + Grand mal epilepsy −
20, SP 3.7 + + + − − − − − nd nd + + −
21, BG 11 + + + + + + − − − (120) + (−4.21) + Severe −
22, BK 18 + + + − − + + − + (9) + (−5.80) + +, Seizures Rickets, facial
dysmorphism
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to the absence of cardinal features such as congenital cataract
[26, 27]. As our study involves only pediatric nephrologists,
underreporting of patients treated by pediatric neurologists
cannot be excluded.
Clinical findings in patients with Lowe syndrome
In this study, we evaluated renal phenotypes in detail, and our
results confirmed a selective tubular dysfunction, as described
by Böckenhauer et al. [3]. Of note, we observed an increase in
the number of different renal manifestations with increasing
age. However, as reported, no patient had the complete renal
Fanconi syndrome [3, 4]. This observation is of clinical rele-
vance, as minimal tubular manifestation in early childhood
should not preclude a diagnosis of Lowe syndrome. Indeed, in
our group of patients, four children aged <4 years (nos. 5, 10,
19, 20), had three or fewer abnormal tubular features. In terms
of specific abnormalities, we found the most prominent dif-
ferences in the presence of RTA, which was observed in two-
thirds of our patients compared to one-third as reported by
Bökenkamp et al. [15], as well as different frequencies for
phosphate and potassium wasting (Table 3). These differences
may be explained by differences in patient age, different
criteria used to define the above abnormalities as well as the
severity of CKD. In fact, it is well known that tubular dys-
function may be aggravated with renal failure [3].
We also observed a high prevalence of CKD (64.3 %),
which is in line with results from previous studies [3, 15].
Importantly, a high percentage (32.1 %) of our patients had
moderate to severe CKD. As suggested by Böckenhauer et al.
[3], we used a k-value of 26, which allows for more accurate
estimation of eGFR in patients with Lowe syndrome due to
their abnormally lowmuscle mass.When original k-values are
used, the calculated eGFR overestimates the true GFR, there-
by resulting in underrecognition of CKD, as reported earlier
[8, 28, 29]. Consequently, a high proportion of patients with
Lowe syndrome may remain underdiagnosed in terms of
CKD, and some abnormalities related to CKDmay be missed.
For example, severe growth deficiency in this tubulopathy
may result, at least to some extent, from CKD-related meta-
bolic abnormalities, although no relationship between short
stature and eGFR has ever been demonstrated—in either a
previous study [15] or in our present study.
Despite normal routine coagulation tests, Lasne et al. [8]
detected prolonged closure times with a platelet-function an-
alyzer in all six patients with Lowe syndrome in their study.
Matzaris et al. [30] demonstrated OCRL-1 protein in human
platelets, providing the link between bleeding disorders and
Lowe syndrome. As patients with Lowe syndrome may have
an increased risk of hemorrhage, coagulation should be tested,
particularly in view of surgery. The platelet-activation anom-
aly was also detected in two of our patients (nos. 1, 6).
Moreover, we found three patients (nos. 3, 5, 24) withTa
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thrombocytopenia; however, this condition may have been
induced by carbamazepine in patient 3 [31] who had received
this anticonvulsant for treatment of partial seizures. In their
very recently published study, Verrotti et al. [32] report that
carbamazepine is associated with hematological disorders that
range from mild thrombocytopenia or neutropenia to anemia
and red cell aplasia, ultimately to bone marrow suppression.
Of note, patients 5 and 24 in our study did not receive any
anticonvulsant drug, and three further patients (nos. 10, 11,
12), also without anticonvulsant therapy, showed a tendency
for thrombocytopenia or low-normal platelet counts. These
findings indicate that depletion of OCRl-1 protein may also
Table 3 Phenotypic findings in
our series of 28 patients with
Lowe syndrome compared with
those reported in the literature
Phenotypic feature Observed in our
cohort
Presence in patients with Lowe
syndrome [15]
Cataract 100 % almost 100 %
Intellectual impairment 100 % 90 %
Growth retardation (mean height SDS) −3.7 −3.08
Low-molecular-weight proteinuria 100 % 100 %
Hypercalciuria 67.9 % 83 %
Nephrocalcinosis/nephrolithiasis 42.9 % 44 %
Aminoaciduria 72.0 % 82 %
Renal tubular acidosis 78.6 % 33 %
Phosphate wasting 57.7 % 43 %
Potassium wasting 44.0 % 21 %
Glycosuria 3.6 % 7 %
Chronic kidney disease (eGFR <90 ml/min/
1.73 m2)
64.3 % 74 %
Table 4 Phenotypic findings in three patients carrying the OCRL p.Asp523Asn mutation
Phenotypic feature Patient no. 4, Italiana,b Brother of patient no. 4, Italianb Patient no. 12, Polish
Age at diagnosis 8 years 2 years 2 years
Eye involvement + (cataract at 8 years) + (megalocornea and optic disc
nuance at 5 years)
+ (cataract at 10 years)
Intellectual impairment − − +
Muscular hypotonia − − +
Growth retardation + (Growth hormone deficienty
at 12 years)
− −
Elevated lactate dehydrogenase/creatinine kinase +/− +/+ +/+
Low molecular weight proteinuria + + +
Hypercalciuria + + +
Rickets − − −
Nephrocalcinosis/nephrolithiasis −/− −/− −/+
Renal tubular acidosis − − −
Aminoaciduria + + trace
Phosphate wasting − − −
Potassium wasting − − −
Glycosuria − − −
Renal failure − − - (But chronic kidney disease)
Other Renal cyst (diagnosis at 7 years) Brain magnetic resonance
imaging: oligogyria
Facial dysmorphy, low-normal
platelet count, elevated serum
transaminases, bilirubin,
and cholesterol
a Initially reported in Tosetto et al. [21]
b Patients not listed in Tables 1 and 2
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have an effect on platelet maturation and/or platelet half-life.
Hence, as outlined by Verrotti et al. [32], careful concomitant
hematological monitoring is needed, especially when carba-
mazepine, phenytoin and valproic acid are used.
Hyperacusis, characterized by over-sensitivity to certain
frequency and volume ranges of sound, was noted in two
patients (nos. 4 and 17) by the respective parents. In the inner
ear, stereocilia are supported on the cuticular plate, a rigid
platform formed by a meshwork of actin filaments in the
apical cytoplasm of the hair cell at the level of the junction
between the hair and its supporting cells. Actin filaments
descend from the stereocilium into the cuticular plate as a
rootlet, which is cross-linked into the actin meshwork [33]. F-
actin dynamics in stereocilia and the cuticular plate are highly
controlled by a network of proteins involving twomammalian
orthologs (FCHSD1 and FCHSD2) of Drosophila Nervous
Wreck [34]. FCHSD1 interacts with Sorting Nexin 9 (SNX9),
an adaptor protein that couples late-stage endocytic coated pits
to actin polymerization [34]. Since OCRL-1 has been shown
to directly bind to SNX9 in Lowe fibroblasts [35], OCRL-1
depletion may also interfere with the correct assembly of actin
in the inner ear.
A similar mechanism might also impair cilia formation on
olfactory receptor cells and hence lead to hyperosmia, an
increased olfactory acuity, which was observed in patient no.
4. According to recent findings, patients with Lowe syndrome
display characteristics of a ciliopathy, with their cells showing
defects in the assembly of primary cilia and in the regulation
of cilia length [36, 37]. Of interest, anosmia, although oppo-
site to hyperosmia, is known to be one of the clinical features
of ciliopathies [38]. Our observations could not be verified by
formal tests, but further studies should systematically address
these findings in order to establish if there is a link between
Lowe syndrome and olfactory and auditive dysfunction.
Genotype–phenotype correlation
The type of mutation in Lowe syndrome and its milder form,
Dent-2 disease, cannot be correlated with the clinical severity
of the conditions. Accordingly, a phenotypic continuum has
been proposed [15], illustrated by two mutations (p.Ile274Thr,
p.Arg318Cys), which initially were associated with only the
mild Dent-2 phenotype [12–14, 39, 40]. However, Hichri et al.
[11] showed that these mutations can also cause the severe
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 
18a 
exo  /  endo  /  phos Rho GAP ASH 
1 
5 
10 
Arg230 
intron 10 
Arg337 
Arg334 
Arg318 Arg663 
Arg493 
Asp   451 
Arg500 
Asp   523 
Arg541 
n = 15 
Arg695 
Arg810 
Arg822 
Arg    844 
n = 12 
Ala861 
patient no. 
Fig. 2 Location and frequency of OCRL mutations affecting CpG
dinucleotides. Black columns Number of patients with classic Lowe
syndrome, hatched columns occurrence of OCRL mutations in milder
affected Dent-2 patients. A schematic diagram ofOCRL1 cDNA is shown
below. Exons are numbered 1–23, and alternative splicing of exon 18a
leads to the in-frame inclusion of eight additional amino acids. Except for
exon 23, the cDNA is drawn to scale and untranslated regions are
depicted in gray [10]. Regions of functional significance in the protein
[exonuclease–endonuclease–phosphatase family domain (exo/endo/
phos), ASPM, SPD-2, Hydin domain (ASH), and Rho GAP-like
domain] are depicted below the cDNA
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classic phenotype, even within the same family. In this sec-
tion, we report several cases of incomplete or evolving Lowe
phenotype, underlining the clinical variability of the disease.
Although cataract is typically one of the first findings in
Lowe syndrome and may even be detected prenatally, patient
12 only displayed the cerebral and renal manifestations of
Lowe syndrome (Tables 2, 4), while cataract was first noted
at the age of 10 years. Interestingly, the p.Asp523Asn muta-
tion observed in this patient has seen reported previously in an
Italian patient [21], and his brother also showed the milder
Dent-2 phenotype (Table 4). Both of these patients showed no
cognitive and intellectual impairment and no muscular hypo-
tonia at the time of the study, but ocular involvement followed
a similar course as that in our patient, with the older brother
developing cataract at the age of 8 years while megalocornea
and optic disc nuance were noted in his younger brother at the
age of 5 years. Of note, patients with megalocornea often
develop presenile cataract [41, 42]. Moreover, brain MRI
revealed oligogyria, a simplified gyral pattern, in this patient.
This feature deserves further attention since it may lead to
cognitive and mental impairment, as well as seizures [43, 44].
Selective and/or growth-dependent organ involvement among
the OCRL mutations is also indicated by two cases, where a
premature termination mutation (p.Gln199X) [27] and a splice
variant (IVS19+1G>A) [26] were associated with a delayed
diagnosis of Lowe syndrome at the age of 13 and 29 years,
respectively. Both these patients had remained undiagnosed due
to the absence of congenital cataract [26] or even any ocular
involvement at all [27]. Also, only minimal signs of tubular
dysfunction and amild behavioral and cognitive phenotype were
found in association with an OCRL p.Glu851X nonsense muta-
tion [45], and a mild renal phenotype was also described due to
an c.1244+5G>A defect [46].
Summarizing all these observations, one might expect ef-
fects of as yet to be identified modifier loci and/or environ-
mental factors to influence the development and/or progres-
sion of clinical features in Lowe syndrome and its milder
variant, Dent-2 disease.
Mutational hot spots in the OCRL gene
A still unexplained, but well-known finding is the location of
prematureOCRL termination mutations. These affect only the
first seven exons in Dent-2 disease and concentrate in exons
8–23 in classic Lowe syndrome [11, 14], as in our study. Other
mutations are scattered throughout the OCRL gene, and none
of these mutations seem to predominate in a given ethnic
background. However, a closer look reveals the well-known
enhancement of C>T/G>A transitions at CpG dinucleotides
mainly affecting arginine codons due to their nucleotide com-
position [47, 48]. In our study, mutations in CpG dinucleotides
account for 42.9 % (n =12) of the mutations observed, and a
de novo origin could be proven in four of these cases
(Table 1). This value is much higher than the data by Hichri
et al. [11] who reported transitions at CpG dinucleotides in 70/
281 (24.9 %) patients, possibly reflecting differences in sam-
ple size. Nevertheless, if data were combined, these occur-
rences represent 82/308 (26.6 %) of all reported OCRL muta-
tions (Fig. 2).
Mutations repeatedly observed may either reflect a founder
effect or repeat de novo events, a question that could not be
solved in case of our intron 10 (c.940-11G>A) mutation,
which was observed twice in Polish patients. A rough estimate
of the lifetime of a mutation in X-linked recessive diseases
was performed by Ten Kate [49], who calculated that the half-
life period of a mutation in Duchenne muscular dystrophy
[fitness (f) of affected carriers = 0] is less than two generations
and that after four generations >90 % of the mutations have
disappeared. Since a similar value of f can be assumed for
patients with Lowe syndrome, the occurrence of an identical
mutation in two unrelated families is probably due to coinci-
dence, and a founder effect is less likely.
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Introduction 
The oculocerebrorenal (OCRL) syndrome of Lowe 
is an X linked, multisystem disorder characterised 
by a triad of abnormalities in the eyes, the nervous 
system and the renal tubules1. It is caused by a 
mutation in the OCRL gene which encodes an 
inositol polyphosphate 5-phosphatase. This enzyme 
has been detected on vesicular structures of the 
endosomal system and the Golgi complex, and 
plays a main role in cellular metabolism. The 
deficiency of this enzyme impairs the maturation of 
polarizing epithelium in neurons and glia, renal 
proximal tubule and lens2. Prevalence of this 
syndrome has been estimated as 1 in 500,000 3. 
 
Case report 
This baby boy was born of a non-consanguineous 
marriage in January 2013 at the Base Hospital, 
Kahawatta and bilateral cataracts were detected at 
birth. On the 4th day of life, baby was referred to 
the Eye Surgeon, Lady Ridgeway Hospital (LRH), 
Colombo. He underwent bilateral trabeculectomy at 
the age of 2 months. At the age of 1 week, baby 
was referred to the Department of Chemical 
Pathology for necessary biochemical investigations 
of cataract by the eye unit.  There is a history of 
delayed milestones. His family tree (Figure 1) 
revealed his maternal cousin to share the clinical 
features.  
 
On physical examination, his weight was 6.2 kg 
less than - 3SD), height was 64 cm (less than -3 
SD) and head circumference was 45 cm (10th 
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centile). He had frontal bossing, flat nasal bridge, 
upward nystagmus, microcephaly, hypermobility of 
joints, hypotonia, severe global developmental 
delay and failure to thrive (Figure 2).  
 
 
 
 
 
The clinical laboratory investigations showed 
hyperchloraemic metabolic acidosis with normal 
serum creatinine.  Serum alkaline phosphatase, 
fasting phosphate, tubular reabsorption of 
phosphate and corrected calcium were 717 U/L (80 
- 480), 1.06 mmol/L (1.45 - 2.16), 84% (> 85%) 
and 2.61 mmol/L (2.2 - 2.7) respectively. Serum 
creatine kinase, lactate dehydrogenase and 
aspartate aminotransferase were elevated. 25-
hydroxy vitamin D level was 46.2 nmol/L 
(deficient ≤50) and parathormone (PTH) level was 
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66.5 pg/ml (10–65). His urine investigations are 
summarised in table 1. X-ray wrist showed delayed 
bone age. Ultra sound scan of the brain was 
normal. 
 
       Table 1: Urine biochemical investigations 
Type of test Result (ref. range) 
Spot test 
pH 
Uric acid: creatinine ratio 
(mmol/mmol) 
Alanine (µmol/L) 
Citrulline (µmol/L) 
Lysine (µmol/L) 
Cystine 
Tyrosine 
Clinistix test for glucose 
 
7.3 (6 - 6.5) 
 
1.64 (0.5 - 1.4) 
7076 (767 - 6090) 
803 (22 - 181) 
2760 (189 - 850) 
Positive 
Positive 
Negative 
24 hour excretion 
Protein (mg/m2/hour) 
Calcium (mmol/kg/day) 
Phosphate (mmol/kg/day) 
 
92 (<4) 
0.12 (<0.1) 
0.7 (0.48 - 0.64) 
 
He was treated with Joule’s solution and Polycitra. 
The clinical diagnosis of Lowe syndrome was 
confirmed by DNA analysis. This revealed a 
hemizygous mutation c. 1427C>T (p.Thr476Ile) in 
exon 14 and carriership was confirmed in the 
mother. Slit lamp examination of eyes of his 
mother did not reveal any abnormalities and her 
renal tubular functions were normal. 
  
Discussion 
Patients with OCRL syndrome, typically present in 
infancy with congenital bilateral cataract, growth 
failure and mental retardation. Cataract manifests 
early in embryogenesis. Congenital or childhood 
glaucoma has been observed in 50% of Lowe 
syndrome patients4. Neurologic manifestations 
include seizures, repetitive behaviour, intellectual 
disability and variable degree of mental retardation. 
Renal tubular dysfunctions include low molecular 
weight proteinuria, albuminuria, aminoaciduria, 
hypercalciuria and phosphaturia which may lead to 
chronic renal failure5.  
 
Our patient was clinically diagnosed on the basis of 
typical occulocerebrorenal manifestations. 
Impaired proximal tubular reabsorption led to 
generalised aminoaciduria, proteinuria, 
phosphaturia, hyperuricosuria and metabolic 
acidosis. He did not have glycosuria which is 
consistent with other reported cases of Lowe and 
indicates selective proximal dysfunction in Lowe 
syndrome patients2. Our patient also had vitamin D 
deficiency. Usually Lowe patients develop vitamin 
D dependent rickets due to impaired activation of 
1-alpha hydroxylase with normal 25-hydroxy 
vitamin D level6. In our case vitamin D deficiency 
led to high PTH and ALP levels. X-rays did not 
show evidence of rickets. 
Hyperphosphaturia and metabolic acidosis due to 
bicarbonate loss are part of the proximal 
tubulopathy of Lowe syndrome or result from PTH 
action on renal tubules. Hypercalciuria may be a 
manifestation of either tubulopathy or vitamin D 
deficiency. Though our patient had hypercalciuria, 
there was no radiological evidence of urolithiasis or 
nephrocalcinosis often reported in OCRL patients7. 
Severe hypotonia is reported in the literature3 and 
our patient also had hypotonia with elevated CK, 
LDH and AST despite of normal liver function. 
Elevation of these enzymes could be due to muscle 
involvement. According to the literature carrier 
mothers with a mild phenotype developed 
aminoaciduria following ornithine loading8 and 
often show eye lesions by slit lamp examination9. 
We could not perform ornithine loading test but eye 
examination did not detect any abnormalities. As 
she is a carrier, she has 25% of possibility of 
having an affected boy and 25% of possibility of 
having a carrier girl in future pregnancies. His 5-
year-old cousin was clinically diagnosed as Lowe 
syndrome and is on treatment however we could 
not perform genetic analysis on him.  
 
More than 200 mutations in the OCRL gene have 
been described in Lowe syndrome patients 
including nonsense, splice-site, missense mutations 
and insertions and deletions10. The missense 
mutation (c. 1427C>T) in exon 14 of the OCRL 
gene observed in our patient had not been 
previously reported. Probably it may be a novel 
mutation in Sri Lanka.    
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Abstract. The oculocerebrorenal syndrome of Lowe is a rare X-linked multisystemic disorder characterized by the triad of
congenital cataracts, cognitive and behavioral impairment and a renal proximal tubulopathy in almost all of the patients. Whereas
the ocular manifestations and severe hypotonia are present at birth, the renal involvement appears within the first months of life.
Patients show progressive growth retardation and may develop a debilitating arthropathy. Treatment is symptomatic and life span
rarely exceeds 40 yr. The causative OCRL gene, encodes an inositol polyphosphate 5-phosphatase. OCRL mutations were not only
found in classic Lowe syndrome, but also in milder affected patients, classified as having Dent-2 disease. There is a phenotypic
continuum within patients with Dent-2 disease and Lowe syndrome, suggesting that there are individual differences in the ability
to compensate for loss of enzyme function. Researchers have conducted a large amount of work to understand the etiology respon-
sible for the disease. However, the mechanisms leading to the clinical manifestations are still poorly understood and we are far from
an effective therapy. In this review, we have included well-established findings and the most recent progress in understanding Lowe
syndrome and Dent-2 disease.
Keywords: Congenital cataracts, cognitive and behavioral impairment, OCRL gene, oculocerebrorenal syndrome, inositol
polyphosphate 5-phosphatase, proximal tubulopathy
1. Introduction
The classic form of the oculocerebrorenal syndrome
of Lowe, first described by Lowe et al. in 1952 [1],
presents with the triad of congenital cataracts, mental
retardation, and renal tubular dysfunction with slowly
progressive renal failure [2,3]. Other features include
postnatal growth retardation independent of kidney
function, areflexia, nontender joint swelling, subcuta-
neous nodules, and arthropathy, which can be observed
in about 50% of adult Lowe syndrome patients [3]. Peri-
ventricular cystic lesions may be identified in some
cases on brain magnetic resonance imaging and a recent
retrospective clinical survey identified defects in platelet
function with increased risk for hemorrhage [4–6].
The molecular basis was later identified as X-linked
mutations in the gene OCRL, encoding an inositol
*Corresponding author: Michael Ludwig, Department of Clinical
Chemistry and Clinical Pharmacology, University of Bonn, Sigmund-
Freud-Str. 25, 53127 Bonn, Germany. Tel.: +49 228 6885 418; Fax:
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polyphosphate 5-phosphatase (IPP-5P) [7]. Interest-
ingly, mutations in OCRL were also found to underlie
some patients with a Dent-like disease, now called
Dent-2 disease, raising the question of how mutations
in the same gene could cause two seemingly distinct dis-
eases [8,9]. The discovery of a Lowe syndrome case
with a more selective organ involvement without any
ocular involvement and patientswithDent-2 disease pre-
senting with mild extra-renal Lowe syndrome-like
symptoms (peripheral cortical lens opacities, stunted
growth, mild intellectual impairment, elevation of serum
creatine kinase (CK)/lactate dehydrogenase (LDH),
implied that Dent-2 disease actually represents a mild
form of Lowe syndrome [8–12].
In this review, we will describe the knowledge of
the molecular background, phenotypic features and ther-
apeutic approaches currently used to ameliorate disease
manifestations.
2. Prevalence of the disorder
Lowe syndrome is a very rare, pan-ethnic disease and
no data reporting its incidence have been published yet.
Dependent on the observations of the American Lowe’s
syndrome Association and the Italian Association of
Lowe’s syndrome, the prevalence has been estimated
to be 1 in 500,000 in the general population [3].
3. Genetic background
The OCRL locus, affected by mutations in Lowe
syndrome and Dent-2 disease patients, was initially
mapped by linkage analysis and the identification of
two balanced de novo X;autosome translocations with
a breakpoint at Xq25–26 in two unrelated Lowe carriers
[13–18]. Subsequently, the OCRL gene was identified
by positional cloning and its genomic structure, compris-
ing 24 exons occupying 52 Kb, has been elucidated
[7,19]. The coding region includes exons 1–23 and alter-
native splicing of exon 18a enlarges the resultant 893
amino acids-long protein by eight (in frame) additional
amino acids [19]. This alternative splicing seems to be
realized in a tissue-specific pattern [20,21]. The reader
should keep in mind that OCRL nucleotide and amino
acid numbering has been updated following the data of
Hichri et al. [22].
The majority of patients (63%) with Lowe syndrome
display frameshift, nonsense or splice defects leading to
mRNA decay or premature termination of the resultant
OCRL-1 protein.Missensemutations and gross deletions
account for 33% and 4% of the cases, respectively [22].
In the milder affected (Dent-2 disease cases), 43% carry
frameshift and nonsense mutations that cluster in exons
1–7, whereas the several missense mutations detected
yet, are spread throughout exons 9–21 [12,22]. No muta-
tion, affecting the alternative exon 18a has been reported
so far. OCRL gene analysis usually comprises all exons
with their corresponding splice sites.With the application
of this strategy, the causative defect remains undetected
in 10–20% of the patients with suspected Lowe syn-
drome [22; own unpublished observation]. Hence, pro-
moter, polyA-site or deep intronic mutations might be
detected in the remaining cases.
The reason(s) why different OCRL mutations mani-
fest with the phenotypic spectrum observed remain(s)
to be elucidated. Although there appear to be remarkable
differences in the distribution of mutations between
Dent-2 disease and classic Lowe syndrome phenotype,
this finding not adequately addresses this question.
Interestingly, a 615 Kb duplication comprising seven
genes, including OCRL, was detected in a boy with aut-
ism and short stature [23]. Although both these features
can also be part of the Lowe syndrome spectrum caused
by deficiency of OCRL-1, they do not necessarily indi-
cate OCRL-1 dysfunction. Hence, this boy cannot be
diagnosed as Lowe syndrome case.
4. OCRL-1 function
OCRL-1 protein, an IPP-5P [7] preferentially con-
verts phosphatidylinositol 4,5-bisphosphate (PIP2),
involved in cytoskeleton-plasma membrane adhesion,
to phosphatidylinositol 4-phosphate [24,25]. Amongst
others, inositol 1,4,5-trisphosphate and inositol 1,3,4,5-
tetrakisphosphate are further accepted subtrates and are
converted into inositol 1,4-bisphosphate and inositol
1,3,4-trisphosphate, respectively. OCRL-1 contains sev-
eral domains involved in various protein-protein interac-
tions. These include an N-terminal pleckstrin homology
(PH) domain, a central 5-phosphatase domain, an
ASPM-SPD2-hydin (ASH) domain, and a C-terminal
RhoGAP-like domain [26]. These interactions and the
several functions of OCRL-1 observed in cellular pro-
cesses are outlined below.
4.1. Endocytosis
OCRL-1 was initially reported to localize to the Golgi
complex [27]. Zhang et al. [28] reported its lysosomal
54 F. Recker et al. / Lowe syndrome
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location in a kidney tubule cell line, however this finding
was not observed in subsequent studies [29,30]. Instead,
OCRL-1 has been detected on vesicular structures of the
endosomal system and the Golgi complex and also on
plasma membrane ruffles and clathrin coated pits
[29–33]. These findings support a role for OCRL-1 in
endocytic trafficking including a possible function in
endosome to trans-Golgi network (TGN) traffic. The
TGN directs proteins to apical or basolateral membranes
in epithelial cells, hence, localization of OCRL-1 to the
TGN implicates a role in trafficking from this compart-
ment. This role may be in delivery of cargo to the endo-
somes, but could also be to the apical or basolateral
membrane [29–34].
OCRL-1 has two clathrin binding sites, the RhoGAP
domain and the N-terminal PH domain [33,35]. Both
play a role in linking OCRL-1 to clathrin, whereby the
RhoGAP domain is probably the more important
domain. OCRL-1 has also been shown to interact with
inositol phosphatase interacting protein of 27 kDa
(IPIP27) A and B (also referred to as Ses1 and 2), regu-
lators of cargo recycling in the endocytic pathway
[36,37]. These two proteins, together with the endocytic
adaptor protein with phosphotyrosine binding, PH
domains and leucine zipper motif (APPL1) harbor a
common OCRL-1-binding phenylalanine and histidine
motif in their C-terminal regions and bind to the
C-terminal ASH and RhoGAP-like domain of OCRL-1
[33,36–38]. IPIP27A and B have been identified as key
regulators of endosomal trafficking linking OCRL-1 to
the recycling of receptors at sorting and recycling endo-
somes [38]. In this context, van Rhaden et al. [39] pro-
vided evidence that OCRL-1 regulates a Rac1-cofilin
signaling cascade mediating retrograde transport of the
mannose 6-phosphate receptor from endosomes to the
TGN. Cofilin, which dependent on PIP2 dephospho-
rylation, regulates F-actin dynamics, seems to be con-
trolled by OCRL-1 and the cofilin mediated actin
turnover, essential for endosome trafficking, is likely
Rac1 dependent [39].
OCRL-1 also directly interacts with Rac1 GTPase in
the TGN and binds to several Rab GTPases with the
strongest interaction with Golgi-associated Rab1 and
Rab6 and endosomal Rab5 [31,40]. Rab binding through
the OCRL-1 ASH domain is required for targeting
OCRL-1 toGolgi and endosomes and directly stimulates
its 5-phosphatase activity [40,41]. A Rab5- and APPL1-
dependent recruitment of OCRL-1 to phagosomes has
also been reported by Bohdanowicz et al. [42].
The functional consequences of all these interactions
with regard to the Lowe syndrome phenotype in almost
all cases remain to be elucidated. The ASH-RhoGAP
domain regulates the most of these protein-protein
interactions, including the multiple clathrin-dependent
trafficking processes [30,32,35]. In that context,McCrea
et al. [43] tested several OCRL missense mutations
affecting this domain. Whereas binding to clathrin and
Rac was not affected by these amino acid substitutions,
all mutations caused disturbance of APPL1 binding
to OCRL-1. This prevented a correct colocalization of
OCRL-1/APPL1 on endosomes, pointing to a substan-
tial role of this interaction in the etiology of Lowe
syndrome [33,43].
4.2. Actin cytoskeleton
Suchy and Nussbaum [44] found that actin remodel-
ing is disrupted in fibroblasts from Lowe syndrome
patients. These authors further reported an abnormal
distribution of gelsolin and alpha-actinin, proteins also
involved in actin dynamics. Actin remodeling is stro-
ngly activated by calcium and a specific increase in
bradykinin-induced calcium mobilization was found in
fibroblasts from Lowe syndrome patients [45]. Hence,
and as mentioned above, changes in actin dynamics
and/or altered membrane traffic may be involved in
the pathology of Lowe syndrome.
4.3. Cell migration and cell-cell contacts
OCRL-1 has also been detected in membrane ruffles
and lamellipodia of COS-7 cells and in fibroblasts from
Lowe syndrome patients [46]. The translocation of
OCRL-1 to membrane ruffles was found to be mediated
by Rac GTPase activation upon growth factor stimula-
tion [46]. As outlined by Faucherre et al. [46], these find-
ings suggest an interference with cellular properties
such as cell migration and formation of cell-cell con-
tacts, which depend on ruffling and lamellipodia within
OCRL-1 depleted cells.
4.4. Polarity
Another role of OCRL-1 has been revealed in epithe-
lial cells at the early stages of polarization [47,48]. Here,
OCRL-1 localized to junctions and formed complexes
with key junctional components. InMadin-Darby canine
kidney and human intestinal epithelial Caco-2 cells, the
authors detected requirement of OCRL-1 for correct
F. Recker et al. / Lowe syndrome 55
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organization of apical and basolateral surfaces. A further
observation supported a polarity defect as these epithe-
lial cells failed to form cysts in 3-dimensional cultures.
Inhibition of this maturation might depend on mis-
targeting apical cargo from recycling apical endosomes
to the lateral membrane. Cell types mainly affected in
Lowe syndrome, i.e. neurons and glia, and renal proxi-
mal tubule and lens epithelium, are highly polarized
and the impairment of maturation of the polarizing
epithelium might contribute to the phenotypic features
observed.
4.5. Cytokinesis
Most recent studies with the Drosophila ortholog
dOCRL revealed another role for OCRL-1 in the cyto-
kinesis machinery and its implication in cell division,
supported by findings in HeLa cells and Lowe syndrome
renal cells where Rab35 controls cytokinesis abscis-
sion through OCRL-1 function [49–51]. As shown by
Dambournet et al. [51], a p.Gly421Glu mutation, found
in a Lowe syndrome patient, caused an increase in PIP2
levels and F-actin at the intracellular bridge, important
for the last step of cell division. These findings are
consistent with the observation of abnormal F-actin
dynamics in fibroblasts from patient cells [44]. As the
addition of F-actin depolymerizing agents at a dose not
perturbing wild type cells, was able to restore normal
amounts of F-actin in Lowe syndrome patient cells, a
therapeutic approach was suggested - that some pheno-
typic features due to OCRL-1 deficiency might be cor-
rectable by reducing increased F-actin levels [51].
4.6. Ciliogenesis
OCRL-1 deficiency affects the same major tissues
(brain, eye, and kidney) as ciliopathy syndromes and
recent studies revealed an involvement of OCRL-1 in
the regulation of ciliogenesis and trafficking processes
to the cilia [48,52,53]. Coon et al. [52] showed that
OCRL-1 is involved in protein trafficking to the primary
cilia in a Rab8- and IPIP27/Ses-dependent manner and
that primary cilia assembly is impaired in patients’ fibro-
blast cells and zebrafish Ocrl morphants. This finding
was corroborated in that Ocrl knockdown in zebrafish
was associated with developmental defects consistent
with disruption of ciliary function, including body
axis curvature, pericardial edema, hydrocephaly and
impaired renal clearance [52,53]. However, whereas
two studies reported reduced cilia length and number
in Lowe syndrome affected fibroblasts and OCRL-1
depleted retinal pigment epithelial cells and kidney tub-
ular cells, Rbaibi et al. [48] detected increased cilia
length in Madin-Darby canine kidney epithelial cells
[52,53]. Although these disparate findings might be
explained by a tissue-specific effect, it is still unclear
how OCRL-1 depletion in ciliary biogenesis and func-
tion may play a role in the pathogenesis of Lowe syn-
drome. The current knowledge has been extensively
discussed by Conduit et al. [54] who assumed that Lowe
syndrome may rather represent a ciliopathy-associated
syndrome.
In conclusion, OCRL-1 localizes not only to multiple
compartments in the endocyctic network (early endo-
somes, clathrin-coated pits, Golgi apparatus and the
basal body) but plays also a role in the maturation of
polarized epithelial cells and in cytokinesis and ciliogen-
esis. A deregulation of all these PIP2-dependent pro-
cesses may explain the pleiotropic phenotypic features
seen in Lowe syndrome.
5. Genotype-phenotype correlation
The type of mutation often predicts the severity of the
respective disease. In case of Lowe syndrome the grade
of severity cannot be correlated to the defect observed.
Hichri et al. [22] reported two mutations (p.Ile274Thr,
p.Arg318Cys) that have been associatedwithmild Lowe
syndrome (Dent-2 disease) [8,9,12,55,56] but can also
cause the severe phenotype even within the same family.
A premature termination mutation (p.Gln199X) and a
splice variant (IVS19+1G>A) were found to be asso-
ciated with Lowe syndrome at patient’s ages of 13 yr
and 29 yr, respectively [10,57]. Both these cases had
remained undiagnosed due to absence of congenital
cataract or even any ocular involvement [10,57]. On
the other hand, only minimal signs of tubular dysfunc-
tion and a mild behavioral and cognitive phenotype
were found in association with an OCRL p.Glu851X
nonsense mutation and a mild renal phenotype was also
described due to an c.1244+5G>A defect [58,59].
These findings are somewhat surprising, since expres-
sion studies performed thus far, showed that all except
two (p.E851X [58], c.40-14A>G [8]) of the frameshift
and nonsense mutations tested, resulted in an almost
complete absence of OCRL mRNA and IPP-5P activity
[8,22,60,61].
The main restriction of the Lowe syndrome pheno-
type to certain epithelial cells of the lens, kidney, and
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the brain remains to be elucidated. OCRL-1 protein
may act in a specific manner in these polarized cells
and/or its deficiency might be compensated by
another IPP-5P, like the inositol polyphosphate 5-
phosphatase (INPP5B), in unaffected tissues [62].
With this assumption, individual variability in such
compensation would explain the differing extent of
symptoms. However, knockout mice for either Ocrl
or Inpp5b provided no clue in that they were viable
with no obvious defects in lens, kidney, or brain
[63]. Instead,murineOcrl and Inpp5b double-knockouts
led to an early embryonic lethal phenotype, implying a
functional overlap of these enzymes inmice. The finding
of species-specific differences in Inpp5b expression and
splice-site choice might be an explanation why Inpp5b
and INPP5B differ in their ability to compensate for
OCRL-1 deficiency [64]. Indeed, Ocrl-/- mice that
expressed human INPP5B, but not the murine ortholog,
showed reduced postnatal growth and cardinal features
of renal tubulopathy [65]. In conclusion, one might
expect effects of yet to be identified modifier loci influ-
encing the phenotype of Lowe syndrome and Dent-2
disease.
6. Lowe phenotype
6.1. Eye
Congenital bilateral cataract is present at birth in
most of the patients and surgical removal with
prompt optical correction is recommended [66–68].
This defect manifests early in embryogenesis due
to defective formation and subsequent degeneration
of the primary posterior lens fibers [67]. Congenital
or childhood glaucoma, observed in around 50% of
Lowe syndrome patients but not reported in Dent-2
disease, should be detected in the first year of life inmost
cases [68,69]. Some are due to cataract surgery. Corneal
opacity (keloid) and a progressive course of corneal
keloids have been observed [70,71]. Other findings were
nystagmus, enophthalmos, anterior polar cataract, sub-
capsular fibrous plaque, capsular excrescences, bladder
cells and posterior lenticonus [67].
More mildly affected (Dent-2 disease) patients may
show no pathologic findings but discrete peripheral opa-
city between nucleus and cortex, as well as mild bilateral
nuclear sclerosis have been observed [11]. Asmentioned
above, Lowe syndrome may remain undiagnosed due
to absence of congenital cataract or even any ocular
involvement [10,57].
6.2. Brain and nervous system
6.2.1. Neuroradiological features
Studies of several Lowe syndrome patients have
shown a wide range of heterogeneity in the white matter
changes ranging from diffuse high-intensity signal to no
demonstrable changes at all. In all cases reported,
hypointense areas were detected in T1-weighted images
whereas they were hyperintense in T2- and proton
density-weighted images [72,73]. These images are
due to gliosis, as has been revealed by proton magnetic
resonance imaging (MRI) spectroscopy where promi-
nent myoinositol peaks, a glial marker suggesting the
presence of gliosis, were present [74]. In addition, even
in fluid-attenuated inversion recovery images, deep
white matter in the periatrial regions was observed [75].
In the central nervous system, the accumulation of
lysosomal products leads to a dilatation of perivascular
spaces, whereas extracellular release of lysosomal
enzymes can lead to toxic gliotic reactions [76]. In com-
parison to this, the spectra from the lesion sites the peaks
of the major metabolites including N-acetyl-aspartate,
choline and creatinine appeared normal [75]. However,
the dual pattern seen in MRI, with a mixture of cystic
lesions and resembling those ofmucopolysaccharidoses,
is due to the accumulation of PIP2. Alteration of deep
white matter as a result of reactive gliosis or demyelina-
tion might be due to the toxicity of the extracellulary
released lysosomal enzymes [76].
MRI also revealed the appearance of cysts in the peri-
ventricular white matter that correspond to perivascular
lacunes [5,74]. These diffuse supratentorial white matter
abnormalities consist of two types: The first one is a
punctate lesion with signal characteristics similar to
those of cerebrospinal fluid. The second pattern consists
of patchy white matter abnormalities that are hypoin-
tense in T1-weighted and hyperintense in T2-weighted
and proton-density images [73]. Even apparent diffusion
coefficient maps demonstrate hyperintense periatrial
lesions although b = 1000s/mm2 images are negative.
Thus, these lesions are responsible for such high appa-
rent diffusion coefficient values (1.76 and 1.66 ×
10−3mm2/s). In the case reported by Sener [75]. it was
summed up that the high values are a combination of
both hyperintensities and punctate cysts, being charac-
teristic for either gliosis or demyelination. This main fea-
ture allows a reinforcement of the clinical diagnosis.
Onur et al. [73] reported a tigroid pattern in the MRI
in one patient with preserved white matter areas with
hypointense radially oriented stripes within the hyperin-
tense cerebral white matter on T2-weighted images.
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This tigroid skin pattern of demyelination has already
been described in Pelizaeus-Merbacher disease, globoid
cell leukodystrophy and metachromatic leukodystrophy,
but never before in Lowe syndrome. Histopathologi-
cally, the white matter foci in this pattern are thought
to be residual islets of preserved myelin, especially
around the blood vessels.
The neuropathological findings reported in the
literature are quite variable and consist of pachygyria,
polymicrogyria, neuronal migration disorder, diffuse
fibrillary gliosis of the centrum semiovale and patchy
demyelination and cerebellar white matter [77]. De
Carvalho-Neto et al. [74] reported brain weight below
normal, atrophy, ventricular enlargement and the thin-
ning of the corpus callosum. These meanings suggest
fibrotic tissue without any inflammatory changes.
Other MRI findings consist of dilated lateral ventricles
and multiple, bilateral well-defined bright spots on
T2- and proton density-weighted images [78].
6.2.2. Seizures
Awidevariability in seizure typeshasbeen reportedby
Charnas [79], who found 15 out of 40 Lowe syndrome
patients with a history of seizures. These included febrile
convulsions, myoclonic seizures and infantile spasms,
staring spells, and mixed staring and generalized tonic-
clonic seizures as the most common type. Recently,
atonic seizures accompanied by focally initiated second-
ary generalized epileptic discharges were added to this
list [80].
Seizure control was obtained in 13 of the 15 patients
reported by Charnas [79], applying phenobarbital and/
or phenytoin, or valproate. In two cases, phenytoin alone
was reported to be effective for controlling brief tonic
seizures and generalized tonic convulsions [78]. Atonic
seizures were reported to be resistant to valproate/
phenytoin/clonazepam therapy, but responded when
lamotrigine was added instead of phenytoin [80]. Use
of the newly-developed vagus nerve stimulation is under
investigation for individuals with Lowe syndrome [81].
6.2.3. Repetitive behavior in Lowe syndrome
Patients with Lowe syndrome often show a very
characteristic pattern of behaviors that can interfere
with everyday functioning. Arron et al. [82] reported
self-injurious behavior and patients harbor a greater
chance for physical aggression. Individuals display
higher scores on measures of autistic-like repetitive
behavior, over activity and impulsivity. A very special
feature existing in Lowe syndrome patients was
inserting objects or body parts as well as repeated
painful biting and even eye-poking [10,82]. The last
feature might be attributable to visual impairment or
may reflect intraocular pain, for instance, from poorly
controlled glaucoma. There is also a great inability to
concentrate or focus and unusual preoccupations or
obsessions [81]. Further, more than 80% of patients
show several maladaptive behaviors including stub-
bornness, temper tantrums and complex repetitive
movements that interfere with adaptive functioning
and are significantly worse than observed in other
visually impaired or comparably mentally retarded
individuals [83]. Lowe syndrome patients scored sig-
nificantly higher than controls on all measures of
maladaptive behavior including aggression, irritabil-
ity and stereotypy, reflected in repetitive, purposeless
movements. Typically, this stereotypy is shown by
hand flapping [83]. Some evidence suggests that the
most difficult period for behavior problems is between
the ages of 8-13 yr. In single cases, these problems can
even continue in adulthood. Here, medication therapy
may be effective including antidepressant and/or anti-
psychotic medications [81].
6.2.4. Intellectual disability
IQ was tested in 47 Lowe syndrome patients. Here,
mean IQ was in the range of 40-54 and 25% of the
affected males showed an IQ of ≥70 [83].
6.2.5. Muscle hypotonia
Muscle involvement in Lowe syndrome includes
severe hypotonia, present at birth and absence of deep
tendon reflexes [3,4]. Muscle biopsy from two Lowe
syndrome patients revealed selective type 1 fiber atrophy
and additionally mild type 1 fiber predominance [84], a
feature also reported by Gobernado et al. [85]. It remains
to be elucidated, if these findings contribute to the eleva-
tion of serum CK, LDH and aspartate aminotransferase
despite normal liver function [86].
The etiology of all these pathological central ner-
vous system features is still unclear. OCRL-1 is highly
expressed in brain and here only the longer splice variant
represents the expressed transcript [20,21]. This isoform
was shown to bind clathrin with higher affinity than the
shorter isoform b, and is significantly more enriched
in clathrin-coated trafficking intermediates [21]. Most
recently, a zebrafish model was shown to recapitulate
several of the neurological findings in Lowe syndrome,
e.g. susceptibility to seizures and cystic brain lesions
[87]. The authors showed that loss of IPP-5P activity
impaired cell survival and reduced cell proliferation
within the developing neurological tissue. Using this
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model, a novel role for OCRL-1 in maintaining Akt sig-
naling and cell survival during embryogenesis was also
identified [87].
6.3. Orthopedic manifestations
Skeletal manifestations, frequently reported in Lowe
syndrome, are osteomalacia and rickets and despite the
presence of normal serum concentrations of vitamin D
metabolites, calcium and phosphorus bone deminera-
lization and recurrent fractures may occur [88–91].
Rickets should be treated with vitamin D and oral phos-
phate supplements. It should be noted, that typically
treatment requires 1-alpha hydroxylated vitamin D, as
uptake of the vitamin D/vitamin D-binding protein com-
plex is necessary for activation by 25-hydroxyvitamin
D-1 alpha hydroxylase, mitochondrial [92]. This may
explain the presence of rickets despite normal vitamin
D levels.
Also often noted were tenosynovitis, joint hypermobi-
lity, joint effusions and contractures [88–90]. Studying
six Lowe syndrome patients, Holtgrewe and Kalen
[93] added scoliosis, kyphosis, platyspondyly, dislo-
cated and/or subluxation of hips, and cervical spine
anomalies to the list of orthopedic deformities. Lowe
syndrome patients may develop a debilitating arthropa-
thy [89,94], not seen in Dent-2 disease patients yet.
These features require correct treatment of rickets and
the therapy of scoliosis, present in about half of the
patients [81].
6.4. Growth failure
Lowe syndrome patients were of short stature when
compared with a control population. Impaired growth
may vary from slight stunting in mildly affected patients
to the well-recognized growth retardation seen in the
severe manifestation. A bone age between height age
and chronologic age and a direct relationship between
age and growth failure in patients with Lowe syndrome
was reported by Charnas et al. [86]. These findings were
confirmed by Bökenkamp et al. [11], who also observed
a similar growth pattern in patients with Dent-2 disease
and Lowe syndrome. The underlying pathophysiology
of growth failure is yet unclear, although it does not
seem to reflect chronic renal insufficiency as height stan-
dard deviation scores were not related to glomerular
filtration rate (GFR) when adjusted for diagnosis and
age [11]. One may speculate that untreated metabolic
acidosis or electrolyte disturbances might account for
growth failure in Lowe syndrome patients.
Growth failure has been treated with human growth
hormone (GH) in some cases but whether this really
changes final height is questionable [12,81]. Whereas
GH application in a single patient showed no effect on
growth at all (D. Böckenhauer, personal communication),
therapywith recombinant humanGH, together with intra-
venous bisphosphonate (pamidronate disodium), was
reported to significantly improve bone turnover and bone
mineral density in another case [95]. However, whether
the change in bone density is permanent or temporary is
still unknown. Given these uncertainties, the invasive
(daily injections) and expensive GH treatment should be
carefully considered.
6.5. Oral and dental manifestations
Anomalies concerning oral and dental features in
Lowe syndrome have rarely been reported and pri-
marily described in isolated cases. Rodrigues Santos
et al. [96], Brooks and Ahmad [97], and Ruellas
et al. [98], have reviewed the many different oral
manifestations seen in the patients. These include
frequently observed eruption cysts or rather specified
dental cysts [96,99–102] and a plenitude of jaw
anomalies, dental abnormalities, periodontal findings
and circumoral features yet observed [97].
However, all these articles mainly describe phenoty-
pic findings without addressing their clinical regime.
This is somewhat surprising since, as outlined in a recent
report, orthodontic treatment can substantially improve
dental esthetics, occlusal function and facial profile,
hence, the quality of live [98]. Prolonged bleeding fol-
lowing tooth extractions has been reported [96,103].
This observation reflects a recent retrospective clini-
cal survey of Lowe syndrome cases, which identified
defects in platelet function with increased risk for
hemorrhage as outlined below [17].
6.6. Kidney
Renal disease in Lowe syndrome is primarily attribu-
table to specific tubular dysfunctions of variable extent
with only low molecular-weight proteinuria and albumi-
nuria present in all patients [2]. There is an obvious
negative relationship between age and GFR [2,11,86].
This may lead to chronic renal failure and end-stage
renal disease requiring dialysis or even transplantation.
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Renal failure was observed in 32% of the milder affected
(Dent-2) patients and in 74% with classic Lowe syn-
drome [11]. As suggested by Copelovitch et al. [104],
focal segmental glomerulosclerosis (FSGS) may occur
secondary to tubular dysfunction or damage. Indeed,
FSGS has been reported in Lowe syndrome and Dent-2
patients [105,106]. Symptoms related to tubular dys-
function are consistent with an impairment of intracellu-
lar trafficking as a key mechanism and include:
6.6.1. Low molecular-weight proteinuria (LMWP)
Proteinuria was noted in the original report of Lowe
syndrome [1] however, it was not assessed according
to size. Today, the presence of low molecular-weight
proteinuria is known as a uniform abnormality in Lowe
syndrome/Dent-2 disease patients and can be identified
just after birth [107]. Especially retinol binding protein
(RBP), with a mean elevation of approximately 1000-
fold above the upper normal limit, has been established
as highly sensitive marker for impairment of tubular
protein absorption [2,108]. All patients showmoderately
elevated urinary albumin. Reabsorption of both these
proteins occurs in the proximal tubule via the megalin
receptor pathway [109–111]. Whether the different
levels of elevation may depend on slight differences in
their reabsorption pathways (albumin is bound also by
cubilin) or rather reflect the difficulties in the assessment
of urinary albumin, which is obviously strongly affected
by glomerular function, is yet unknown [110]. On the
other hand, one can argue that retinol binding protein
is freely filtered and exclusively reabsorbed in the proxi-
mal tubule, whereas only a fraction of albumin is filtered.
This alonemay explain the discrepancy in themagnitude
of urinary levels. Cui et al. [34] found no defect in the
trafficking and function of megalin upon OCRL-1
siRNA knockdown and assumed that the renal manifes-
tations in Lowe syndrome are downstream from endocy-
tosis or postendocytic membrane trafficking. However,
the paper byVicinanza et al. [111] reported the opposite,
i.e. a megalin trafficking defect.
6.6.2. Aminoaciduria
Organic aciduria (which included amino acids) has
been part of the initial description [1] and has been
detected in most patients with Lowe syndrome [2,86,
112]. In one report, it was noted to spare branched-
chain amino acids, but results typically showed gen-
eralized aminoaciduria, although with considerable
variability between patients [86]. Whereas amino-
aciduria is observed in around 82% of classic Lowe
syndrome patients, it manifests in only 52% affected
with Dent-2 disease [2,11].
6.6.3. Lysosomal enzymuria/hyperenzymemia
Urinary lysosomal enzymuria by determination of
N-acetyl-beta-d-glucosaminidase has only rarely been
assessed in with patients Lowe syndrome but in those
cases uniformly showed elevated levels [2,107,113].
This feature was linked to altered intracellular trafficking
of the cation-independent-mannose-6-phosphate recep-
tor, required for the directed recognition and vesicular
transport of lysosomal proteins [114]. Norden et al.
[113] proposed a mis-trafficking via a default pathway
delivering lysosomal enzymes from the Golgi to the api-
cal membrane of proximal tubule cells and excluded cell
necrosis as a possible cause. On the other hand, Nielsen
et al. [115] reported evidence against a primary defect in
intracellular sorting. Hence, the underlying mechanism
still remains to be elucidated.
Ungewickell and Majerus [116] measured plasma
levels of seven lysosomal enzymes and found a 1.6- to
2.0-fold increase of all enzymes in all patients tested.
These authors also postulated a defect in lysosomal
enzyme trafficking, leading to the observed increase
and suggested that this may cause a tissue damage in
Lowe patients. The increased enzyme levels however,
could not be attributed to renal insufficiency [116].
6.6.4. Hypercalciuria/nephrocalcinosis
Urinary calcium excretion had not been assessed in
the original three patients described by Lowe et al. [1],
and was not noted in a later series of 23 patients [86].
However, other studies described it as uniformly pre-
sent in Lowe syndrome and Dent-2 disease patients
[2,11,117–119]. Therapy with potassium citrate might
be useful to reduce renal calcium excretion and to
prevent nephrocalcinosis. Since citrate is metabo-
lized to bicarbonate, citrate treatment may also correct
co-existing tubular acidosis. When applying thiazide,
which should be considered very carefully, hypokalemia
and hyponatremia should be monitored. These patients
have already impaired proximal tubular reabsorption
with consequent polyuria and salt wasting. Hence, to
pharmacologically paralyze another tubular segment
makes them extremely vulnerable to hypovolemia. To
our knowledge, only one Dent-2 disease patient has been
reported by Vrljicˇak et al. [120] who has been treated
with hydrochlorothiazide in combination with amiloride
and K-Na-citrate. Here, the authors reported a good
response in reducing calciuria.
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Nephrocalcinosis and/or calculi occurred in 67% of
patients (nine of 15 assessed), reported by Böckenhauer
et al. [2] and in 39% of Dent-2 disease cases [11]. Inter-
estingly, this finding is not explainable by the degree of
hypercalciuria, nor was it obviously related to age [2].
Hence, the transport pathway for calcium in the proximal
tubule, although yet to be defined, is clearly affected by
OCRL-1 dysfunction. However, a most recent observa-
tion provided evidence for a direct effect ofOCRLmuta-
tions on intestinal calcium transport. Wu et al. [121]
investigated, whether the intestinal calcium channel
transient receptor potential, vanilloid subfamily, subtype
6 (TRPV6) is regulated by OCRL-1. TRPV6 mediates
active calcium absorption and its expression at the apical
surface of intestinal epithelial cells increases in response
to 1,25-dihydroxyvitamin D3. The authors showed
that the Rab binding domain of OCRL-1 was involved
in regulating the trafficking of TRPV6 and examined
the effect of several Dent-2 disease OCRL missense
mutations. In a Xenopus laevis oocyte expression
system, OCRL-1 suppressed TRPV6 activity through
modulation of PIP2 levels. All mutants reduced this
suppression and increased TRPV6-mediated intestinal
calcium absorption, thereby, together with the altered
calcium reabsorption in the proximal tubule, providing
another clue for hypercalciuria in Dent-2 disease/Lowe
syndrome [121].
6.6.5. Acidosis
Metabolic acidosis was present in all three children
described by Lowe et al. [1]. In a subsequent review
of 70 cases, 65 had values for blood carbon dioxide
content available, which was normal in 12 (18%)
[112]. Similarly, in later reviews, 35% (8/23) and
56% (9/16) of the children did not require alkali substi-
tution to maintain acid-base balance [2,86]. Renal tub-
ular acidosis was detected in only 1 out of 27 patients
with mild Lowe syndrome (Dent-2 disease) but in
one-third (11/33) of classic Lowe syndrome cases
[11]. However, as outlined by Böckenhauer et al. [2]
plasma total carbon dioxide concentration was typically
found at the lower end of normal. These authors sug-
gested that a more detailed investigation of renal ammo-
nia production and urine acidification, as performed
originally, might well reveal subclinical abnormali-
ties [1]. Interestingly, Lowe et al. [1] argued that the
decreased production of ammonia actually set his
patients apart from those with renal Fanconi syndrome,
in whom a strongly increased amount of ammonia were
detected [122].
6.6.6. Phosphaturia
Phosphaturia was not noted in the first reported
patients who had low to normal serum phosphate levels
[1]. In an extensive review, 61% (14/23) did not require
phosphate supplementation [86]. Four of seven Korean
patients had hypophosphatemia and in another series,
phosphate wasting was detected in 24% (6/25) of
Dent-2 disease patients and in 43% (16/37) with classic
Lowe syndrome [11,119]. Obviously, assessment of
phosphaturia may be complicated by the often-present
elevated parathyroid hormone levels (PTH). TmP/GFR
(tubular maximum for phosphate reabsorption) values
in the patients reported byBöckenhauer et al. [2] all were
obtained while PTH levels were normal, and seven of
16 patients investigated required 1-OH cholecalciferol
substitution to keep PTH in the normal range. Thus,
the low serum phosphate values in the original series
may be partly due to secondary phosphaturia mediated
by PTH, rather than primary phosphaturia from tubular
dysfunction.
6.6.7. Glycosuria
In reviews of Lowe syndrome patients, glucose was
only occasionally detected in the urine and then in mar-
ginal amounts [2,11,86,112,119]. This is obviously in
contrast to other cases of renal Fanconi syndrome, in
whom glycosuria is a defining feature and argues
strongly for a selective proximal dysfunction in Lowe
syndrome [94].
6.6.8. Poor renal accumulation of technetium-99
m-dimercaptosuccinate (99mTc-DMSA) in
Lowe syndrome proximal tubular dysfunction
An abnormal handling of 99mTc-DMSA has been
reported in children with idiopathic tubular proteinuria
(Japanese Dent’s disease) [123]. Poor accumulation of
99mTc-DMSA in the kidneys with high bladder con-
tent of the radionuclide was also found in a total of
seven patients with Lowe syndrome and three Dent-2
disease cases [124,125]. A similar abnormal radionu-
cleotide distribution could be detected in other tubular
disorders, like Fanconi syndrome, distal renal tubular
acidosis and nephronophtisis, even in case of a nor-
mal GFR [126–128]. There is still uncertainty how
99mTc-DMSA reaches the bladder since its handling
is very complex in the kidneys: it is filtered via the glo-
merulus and taken up from both the brush border and
basolateral membrane of renal tubular cells, in a cotran-
sporter mode together with sodium [129,130]. Hence,
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the presence of 99mTc-DMSA in the bladder might be
due to an impaired tubular reabsorption as it is known
for sodium, phosphate, uric acid, glucose, low molecu-
lar weight proteins, and amino acids. Since 99mTc-
DMSA visualization of the kidneys occurs by uptake
into tubular cells, poor visualization of the kidneys
might be explained by failure to extract from the blood
or excretion into the tubular lumen. Irrespective of
these open questions, 99mTc-DMSA renal scans might
be used as diagnostic tool to evaluate functional tubular
mass, which depends on the renal blood flow and prox-
imal tubular cell membrane transport function in Lowe
patients. It would also be interesting, if an abnormal
pattern might also be detectable in female carriers of
OCRL mutations.
7. Further laboratory findings
7.1. Elevated serum CK/LDH
Levels of serum CK, LDH or both were elevated in
most patients withDent-2 disease and all cases with clas-
sic Lowe syndrome for whom these measures were
available [11,12,124]. The origin of the CK and LDH
level elevation is yet unclear and may reflect muscle
involvement or nonspecific damage in cell membranes
in the kidney because both, CK and LDH, were reported
to be involved in the metabolism of proximal tubular
cells [36,82].
7.2. Hypocarnitinemia
In about one-third of Lowe patients a decrease in
plasma carnitine concentration has been observed, that
can be treated by oral carnitine therapy [131].
8. Hemostasis
Aside from normal coagulation tests, Lasne et al. [6]
detected prolonged closure times with a platelet-function
analyzer in all six Lowe patients tested. Matzaris et al.
[62] initially detected OCRL-1 in human platelets and
these novel findings provide evidence that the platelet-
activation anomaly observed might be due to an
impaired Rho-dependent signaling caused by decreased
OCRL-1 protein. Since data implicate an increased
hemorrhagic risk, Lowe syndrome patients should be
tested for hemostasis defects, particularly in view
of surgery. It has been shown that tranexamic acid
improves platelet function in patients with chronic renal
failure and it also ameliorates platelet dysfunction in
Lowe syndrome patients (D. Böckenhauer, personal
communication) [132]. This should be considered pre-
surgery or in case of an actively bleeding.
9. Reproductive anomalies
About one-third of the patients show cryptorchidism,
but in most instances testes descend into the scrotum
without hormone therapy or surgical intervention.
Delayed onset of puberty has been reported [81].
10. Dermatological findings
There are just a few reports regarding Lowe syn-
drome and dermatological features. Erdoğan et al.
[80] found a benign cyst skin tumor, unlike a vellus
hair cyst. The interior material originated from
mature hair follicles. Epidermal examination issued
a nodular lesion and diagnosis revealed trichoepi-
telioma. Based on the biochemical deficiencies, an
OCRL mutation was assumed. Nandekar et al. [133]
reported that benign skin findings may be more com-
mon in Lowe syndrome. In one case, an eruptive vellus
hair cyst was presented and abnormal high levels of
extracellular lysosomal enzymes, leaving these enzymes
free to cause tissue destruction, were found. The authors
suggested, that the cyst formation is a result of localized
reaction intended to wall off the destructive enzymes,
which means the loss of cellular control due to
accumulation of PIP2 and the extracellular release of
lysosomal enzymes. Otherwise, cyst formation may
be due to polarity defects as in ciliopathies, since
OCRL-1 has been shown to be involved in ciliogenesis
[48,52,53].
A further case presented with multiple eruption
cysts in the oral cavity and hematoma formation
[98]. Won et al. [134] found various skin lesions
reported to be skin colored, deep seated, with soft cys-
tic masses on the temporal and occipital scalp. The
histological examination showed each cyst to be lined
by true epidermis composed of several layers of stra-
tified squamous epithelium and a granular layer con-
taining keratinous materials arranged in laminated
layers. Most recently, a Lowe syndrome patient
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presenting with multiple skin folds and an increase in
subcutaneous fat has been reported [135].
11. Unusual findings in association with
Lowe syndrome
In a patient with tubular proteinuria, dysmorphic
features, rickets, growth delay, mild cognitive and beha-
vioral impairment, and peripapillary optic nerve atrophy
with grey papillae, the co-inheritance of a CLCN5- and
OCRL-mutation was found by Addis et al. [136]. The
OCRL splice defect observed (c.388+3A>G) locates in
the region typically affected in Dent-2 disease cases and
the authors suggested, that here the phenotype resulted
from synergic interaction between the two mutations. In
two Lowe patients who died at the age of 45 and 4 d,
respectively, pronounced glomerular changes attributable
to congenital nephrotic syndrome, were reported [137].
Elevated high-density lipoprotein cholesterol (HDL-
C) levels are present in around 65% of Lowe syn-
drome patients [82]. In three patients with elevated
HDL-C, Asami et al. [138] detected a heterozygous
p.Asp442Gly mutation in the gene encoding cho-
lesteryl ester transfer protein (CETP) in one of these
patients and assumed this as a possible cause of
increased serum HDL-C. The finding of homozygous
cystinuria and Lowe syndrome in one family was
described by Bailey et al. [139]. In one patient, where
diagnosis was only based on decreased IPP-5P activity
in cultured skin fibroblasts and not onOCRL gene ana-
lysis, anal atresia has been reported in association with
Lowe syndrome [102]. Further findings were sensori-
neural deafness, found unilaterally in one patient [12].
Congenital diaphragmatic hernia has been descri-
bed once in association with classic Lowe syndrome
whereas umbilical hernia was found twice in patients
with Dent-2 disease [12,140]. However, all these
occurrences might rather represent a coincidence than
features attributable to an OCRL-1 defect.
12. Female carriers
The investigation of 98 mothers of Lowe syndrome
patients revealed a de novo mutation in 37.2% of the
cases and hence one might assume maternal carriers
in around two-third of the occurrences [22]. As in other
X-linked diseases, carriers may show a mild pheno-
type. Following ornithine loading, aminoaciduria was
reported in one carrier and other features, i.e. [141].
LMW proteinuria might at least in part, be attributable
to unfavorable lionization. In most of the carriers, slit
lamp examination reveals punctuate white to grey opa-
cities, distributed in a radial fashion in all layers of the
lenticular cortex [142–144].
Heterozygous females may manifest a more complete
phenotype due to several mechanisms and a total of ten
cases have been reported in the literature. Cytogenetic
abnormalities like a reciprocal translocation involving
the X-chromosome have been found in two Lowe syn-
drome carriers [17,18]. Otherwise, the cause might be
attributable to a 45,X karyotype, uniparental disomy or
an extremely skewed X-inactivation, like the pattern
with a ratio of 100:0 detected in a carrier with the full
Lowe syndrome phenotype [145]. The causative defect
was not ascertained in a further seven cases [146–152].
On the other hand, completely skewed X-inactivation
of the OCRL mutation carrying X-chromosome was
observed in a healthy carrier [136].
13. Genetic counseling
It should be kept in mind, that there is a large pheno-
typic continuum within OCRL positive patients and that
there may be selective organ involvement with i.e.
absence of any ocular involvement [10]. As outlined
above, Lowe syndrome can be attributed to a de novo
mutation in around one-third of the cases [22]. Although
not frequent, the presence of germline mosaicism has to
be taken into account. Mosaicism for a single point
mutation has been observed in five Lowe families yet
and two families showed mosaicism with two de novo
events [10,22,153–155]. In one of these cases, triple
mosaicism, affecting a single nucleotide residue was
observed in the carrier mother [155].
14. Prenatal diagnosis
In families, where the OCRL mutation is known,
genetic diagnosis can be performed following chorionic
villi or amniotic fluid sampling [156]. In other cases,
early detection of Lowe syndrome might be achieved
bymeasuring the IPP-5P activity in cultured amniocytes,
elevated maternal serum and amniotic fluid alpha-fetal
protein, or by the diagnosis of fetal cataract [157–161].
A recent report described increased fetal nuchal translu-
cency in two cases with Lowe syndrome [162].
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15. Perspectives
In conclusions, without the invaluable contributions
of the several Lowe syndrome self-help groups many
of the current findings of this very rare disorder would
not have been obtained. Although a lot of experi-
mental results, phenotypic descriptions and therapeutic
approaches have been published, we still only pieced a
few parts of the puzzle in the sixty years since the first
description of Lowe syndrome [1]. Utilization of zebra-
fish and novel mouse models may reveal hitherto unrec-
ognizedmechanisms by which OCRL-1 deficiency leads
to the phenotypic spectrum of the syndrome. This will
also lead to the recognition of further proteins involved
in the networks affected. The better understanding of dis-
ease etiology may provide the basis for developing the-
rapies and preventive strategies i.e. for renal function.
Further studieswill help to clarify, if the phenotypic varia-
bility is either caused by different effects of mutations/
variants in other genes and/or might be attributable to
environmental effects.
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CLINICAL UTILITY GENE CARD
Clinical utility gene card for: Lowe syndrome
Arend Bo¨kenkamp*,1, Elena Levtchenko2, Florian Recker3 and Michael Ludwig3
European Journal of Human Genetics (2014) 0, 000–000. doi:10.1038/ejhg.2014.177
DISEASE CHARACTERISTICS
1.1 Name of the disease (synonyms)
Lowe syndrome.
Oculocerebrorenal syndrome.
Oculo-cerebro-renal syndrome.
OCR syndrome.
1.2 OMIM# of the disease
Lowe syndrome (MIM #309000).
1.3 Name of the analyzed genes or DNA/chromosome segments
OCRL , Xq25–q26.1.
1.4 OMIM# of the gene(s)
OCRL , 300535.
1.5. Mutational spectrum
The OCRL gene was identified by positional cloning1 and its genomic
structure, comprising 24 exons occupying 52 kb, has been elucidated.2
Since then, more than 200 Lowe syndrome patients with OCRL
defects have been identified, which were extensively reviewed by
Hichri et al.3 Disease-causing variants are scattered throughout the
gene and the majority of patients (63%) display frameshift, nonsense
or splice defects3 leading to mRNA decay or premature termination of
the resultant OCRL-1 protein. Missense variants and gross deletions
account for 33 and 4% of the cases, respectively.3 No variant affecting
the alternative exon 19 has been reported so far.
Human wild-type OCRL gene and OCRL-1 protein with their
corresponding exon and amino acid numbering are deposited in
GenBank, acc. nos. NM_000276.3 and AAB03839. OCRL variants are
included in the Human Gene Mutation Database (http://www.hgmd.
org/) or can be obtained via the Leiden Open Variation Database
(http://www.ncbi.nlm.nih.gov/lovd/home.php?select_db=OCRL).
1.6 Analytical methods
Bi-directional Sanger sequencing of PCR-amplified products compris-
ing the total coding region and the exon–intron boundaries of the
OCRL gene. For detection of genomic OCRL rearrangements and/or
precise gene quantification, the multiplex ligation-dependent probe
amplification might be used.4
1.7 Analytical validation
Confirmation of the detected variant at least from a second amplicon,
preferentially from an independent biological sample of the index
case. Pathogenicity of novel missense variants has to be verified by
(i) testing a set of at least 100 chromosomes from normal ethnically
matched controls, (ii) considering its deposition in SNP databases
and (iii) using in-silico prediction methods. Gene transcripts should
be analyzed in case of splice variants. The gold standard is analysis of
functional consequences of the respective OCRL variant in cell
models, performed in a few laboratories in the world.3,5–7 In case
of suspected splice site variants, OCRL mRNA should be analyzed.
1.8 Estimated frequency of the disease (incidence at birth (‘birth
prevalence’) or population prevalence)
1:500,000.8
If known to be variable between ethnic groups, please report)
Not applicable.
1.9 Diagnostic setting
Yes No
A. (Differential) diagnostics 2 &
B. Predictive testing 2 &
C. Risk assessment in relatives 2 &
D. Prenatal 2 &
Comment: In affected boys, bilateral cataracts, one of the cardinal
symptoms of Lowe syndrome, develop in utero and are almost
invariably present at birth.3,8,9 Other ocular findings include
microphthalmia, enophtalmos and glaucoma, the latter developing
in the first three decades in 50–60% of the patients. About 25% of
Lowe syndrome patients have corneal scarring and keloids.
CNS pathology manifests as neonatal and infantile hypotonia with
areflexia and delay in motor development.8 Seizures are observed in
about half of the patients. Typically, patients have mildly elevated
creatine kinase and/or lactate dehydrogenase levels.10 Intellectual
disability is a cardinal finding with only 10% of patients having
normal intelligence. Behavioral abnormalities (stereotypic behavior,
self-injury, tantrums, aggression/irritability, repetitive non-purposeful
movements) are common, too.
The renal phenotype is characterized by proximal tubular dysfunc-
tion. Impaired reabsorption of low-molecular-weight proteins is
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present in all patients, while disturbances in other tubular functions
are variable:10,11 Generalized aminoaciduria in 80%, phosphate and
potassium wasting (in 40 and 20%, respectively), proximal renal
tubular acidosis in 35% and slowly progressive renal failure leading to
end-stage renal failure in the second and third decade. Unlike other
tubular functions, glucose reabsorption is less affected. Like patients
with Dent disease (see below), the majority of patients have
hypercalciuria (80%), while nephrocalcinosis is observed less often
(40–50%). The pattern of tubular dysfunction in the two forms of
Dent disease and Lowe syndrome was compared by Bokenkamp
et al.10
Additional features of Lowe syndrome are postnatal growth
retardation and a debilitating non-inflammatory teno-arthropathy
present in 50% of adult patients.
In a subgroup of patients with OCRL variants, the clinical
phenotype is dominated by the renal manifestations of the disease
and the ocular and cerebral findings are very subtle. These patients are
classified as having Dent-2 disease (MIM #300555).10,12 Reported
extra-renal abnormalities were mild growth retardation, clinically
unapparent cataract in 2/28, subtle mental retardation in 9/23 and
elevated creatine kinase or lactate dehydrogenase in all.10 In selected
cases the classification as Lowe syndrome or Dent-2 disease can be
somewhat arbitrary. The characteristics of the two forms of Dent
disease and Lowe syndrome are summarized in Table 1.
2. TEST CHARACTERISTICS
2.1 Analytical sensitivity
(proportion of positive tests if the genotype is present)
Close to 100%. The sensitivity of sequence analysis of PCR-
amplified products approaches 100%. Many variants have been tested
functionally, and the pathogenicity of most variants has been
predicted by publically available algorithms. Nonetheless, errors may
occur due to allele dropout and variants outside the coding region in
the promoter, polyA site, enhancers or intronic variants may be
missed.
2.2 Analytical specificity
(proportion of negative tests if the genotype is not present)
Nearly 100%. In rare cases, variants may erroneously be interpreted
as pathogenic.
2.3. Clinical sensitivity
(Proportion of positive tests if the disease is present)
Variants in OCRL account for 80–90% of cases with a phenotype of
Lowe syndrome.3
2.4 Clinical specificity
(proportion of negative tests if the disease is not present)
100%.
2.5 Positive clinical predictive value
(lifetime risk to develop the disease if test is positive)
Almost 100%. Still, a small number of patients with OCRL variants
have a predominantly renal phenotype and are classified as having
Dent-2 disease on clinical grounds. In a large series, 6 out of 136
families with an OCRL variant were classified as Dent-2.3 There have
been incidental reports of Lowe syndrome and Dent-2 in patients
harboring the same variant, even within one family.3
2.6 Negative clinical predictive value
(Probability of not developing the disease if the test is negative)
Almost 100%, still in some patients with clinical features of Lowe
syndrome no OCRL variants were detected.3
3. CLINICAL UTILITY
3.1 (Differential) diagnostics: the person is clinically affected
3.1.1 Can a diagnosis be made other than through a genetic test?
No & (continue with 3.1.4)
Yes 2
Clinically 2
Imaging &
Endoscopy &
Biochemistry 2
Electrophysiology &
Other (please describe): Ophthalmological examination
Comment: The Q1combination of all three diagnostic domains is
diagnostic.
Slit-lamp examination can be used for identification of female
carriers.8
3.1.2. Describe the burden of alternative diagnostic methods to the
patient
The alternative methods to diagnose Lowe syndrome are generally
non-invasive. The diagnosis of Lowe syndrome is suggested by
congenital cataract, which is almost uniformly present. Recognition
of the cerebral manifestations is based on a thorough neurological
examination. The biochemical diagnosis of Lowe syndrome is not
invasive (spot urine for low-molecular-weight proteinuria, hypercal-
ciuria and variable presence of other proximal tubular dysfunctions).
3.1.3 How is the cost effectiveness of alternative diagnostic methods
to be judged?
The cost effectiveness of the physical examination in combination
with an ophthalmological examination and simple biochemical tests
is high.
3.1.4 Will disease management be influenced by the result of a
genetic test?
Not for Lowe syndrome. In patients with the mild Dent-2 phenotype,
who might be missed clinically, nephrological follow-up is warranted.12
Table 1 Clinical and laboratory characteristics of Lowe syndrome
compared with Dent-1 (CLCN5 mutation) and Dent-2 (ORCL
mutation) disease8–10
Dent-1 (CLCN5þ ) Dent-2 (OCRLþ ) Lowe (OCRLþ )
Cataract No 10% (asymptomatic) Almost 100%
Intellectual impairment No 30% (mild) 90%
Growth retardation No Postnatal, mild
("1 to "2 SD)
Postnatal, severe
("2 to "6 SD)
Elevated LDH or CK 36% 100% 100%
LMW-PU 100% 100% 100%
Hypercalciuria 90% 86% 83%
Nephrocalcinosis 75% 39% 44%
Aminoaciduria 41% 52% 82%
RTA 3% 4% 33%
Phosphate wasting 22% 24% 43%
Potassium wasting 15% 6% 21%
Glycosuria 17% 11% 7%
Renal failure 30% 32% 74%
Abbreviations: CK, creatine kinase; LDH, lactate dehydrogenase; LMW-PU, low-molecular-
weight proteinuria; RTA, renal tubular acidosis; SD, standard deviation.
Clinical Utility Gene Card
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3.2 Predictive setting: the tested person is clinically unaffected but
carries an increased risk based on family history
3.2.1 Will the result of a genetic test influence lifestyle and prevention?
Not for Lowe syndrome. In case of the milder Dent-2 phenotype,
nephrological follow-up should be initiated.12
3.2.2 Which options in view of lifestyle and prevention does a person
at risk have if no genetic test has been done?
Urine could be tested for the presence of low-molecular-weight
proteinuria, which is an obligate finding in Dent-2 disease. In case
of Dent-2 disease, nephrological follow-up should be initiated.12
3.3 Genetic risk assessment in family members of a diseased person
3.3.1 Does the result of a genetic test resolve the genetic situation in
that family?
Yes.
3.3.2 Can a genetic test in the index patient save genetic or other
tests in family members?
Yes. If the index case has known mutations, siblings, parents and other
family members can be screened for disease by ophthalmological
examination and urine analysis for low-molecular-weight proteinuria.
3.3.3 Does a positive genetic test result in the index patient enable a
predictive test in a family member?
Yes. Still, variable clinical expression has to be considered (cf. 2.5).
3.4 Prenatal diagnosis
3.4.1 Does a positive genetic test result in the index patient enable a
prenatal diagnosis?
Yes. Still, variable clinical expression has to be considered (cf. 2.5).
4. IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate
medical consequences. Is there any evidence that a genetic test is
nevertheless useful for a patient or his/her relatives:
Establishing an unequivocal molecular diagnosis may be helpful for
the family.
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